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Dyneins are protein motor complexes that generate force towards the minus ends of 
microtubules, and cytoplasmic dynein plays a variety of important roles in cell. A small library 
of synthetic chemicals based on the natural product purealin was first examined for inhibition of 
cytoplasmic dynein heavy chain and cell growth. The compounds showed effective 
antiproliferative activity against a mouse leukemia cell line, but selective activities against a 
small panel of human carcinoma cell lines. Purealin and some of its analogues showed 
concentration-dependent inhibitory effects against the microtubule-stimulated ATPase activity of 
both bovine cytoplasmic dynein heavy chain as well as the recombinant motor domain of human 
cytoplasmic dynein in an uncompetitive pattern, indicating that they do not compete with the 
binding of ATP. Purealin also weakly inhibited p53 nuclear accumulation after DNA damage. 
Small interfering RNAs of cytoplasmic dynein heavy chain were also tested as a positive control 
in this assay, although the lifetime of the protein turned out to be too long for the siRNA 
approach to be useful in a screening protocol. 
A strategy was built to screen for dynein inhibitors based on a GFP-GR nuclear 
translocation assay by using a mouse mammary adenocarcinoma cell line (3617.4) stably 
expressing the fluorescent protein. A small library of synthetic compounds was screened for 
inhibition of hormone-stimulated GFP-GR nuclear translocation. Several compounds were found 
to elicit the desired phenotype, and these compounds inhibited the ATPase activity of 
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cytoplasmic dynein heavy chain motor domain without competing for the hydrolyzable ATP-
binding site. Biochemical specificity tests showed that the compounds did not compete for GR 
binding nor inhibit the ATPase activities of Hsp70, Hsp90 or myosin.  
Libraries of compounds designed to be Hsp70-perturbing agents were also evaluated. 
Previous data showed that the Hsp70 chaperone class is induced in certain breast cancer cells and 
that antisense-mediated knockdown of Hsp70 triggers apoptosis, indicating that Hsp70s 
represent a new target for breast cancer therapy. A small molecule inhibitor of Hsp70 co-
chaperone interaction (MAL3-101), as well as several analogues, showed antiproliferative 
activity against SK-BR3 breast cancer cells. 
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1.0  INTRODUCTION 
The aims of cancer researchers is not only to identify new structural classes of agents to 
selectively attack the disease, but also to aim at new targets. In this work, cytoplasmic dynein 
and Hsp70 were chosen as drug targets that are both unique and challenging. The first goal of 
this project was to develop a high throughput and high information content screening system for 
examining libraries of compounds as potential inhibitors of the molecular motor cytoplasmic 
dynein. Through wise selection of screening strategies and new methods for compound 
evaluation, chemical biology tools and even novel therapeutic agents could be found. The second 
goal of this project was to evaluate Hsp70-targeting agents as anti-breast cancer agents. In both 
cases, the biological activities measured for library members will allow structure-activity 
relationship (SAR) development, which should aid in the discovery of more portent and/or 
selective agents. Also, the biological character of the drug target as well as the molecular 
mechanisms of action for a given agent could be evaluated. This results from this project will 
provide a cornerstone for these goals. 
1.1 Microtubule and microtubule-associated proteins 
Microtubules (MTs) are intracellular tubes of regular circumference that form 
cytoskeletal lattices and the mitotic spindle. They are built and dismantled by the dynamic 
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assembly/disassembly of heterodimers of the ~50 kDa proteins α- and β- tubulin, of which 
several isotypes for each monomer exist in mammalian systems1. The tubulin/microtubule 
system is a proven clinically useful antitumor target. Examples of chemotherapeutics that act via 
perturbation of tubulin polymerization include paclitaxel, docetaxel, vinblastine and 
discodermolide2-5 (Figure 1). 
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Figure 1. Chemical structures of two microtubule depolymerization inhibitors: paclitaxel 
and discodermolide  
 
There is a large group of microtubule(MT)-associated proteins, or MAPs6, that bind 
microtubules, acting mainly to stabilize them against disassembly. The binding of MAPs to 
microtubules is largely dependent on MAP phosphorylation status, making them targets for 
protein kinases. Major MAPs include MAP1, MAP2, MAP4 and tau. MAP4 is the most 
abundant and ubiquitous MAP in non-neuronal cells that stabilizes microtubules7. 
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1.2 Motor proteins and motor protein inhibitors 
Motor proteins are amazing biological machines that are responsible for most forms of 
movement in cells. Motor proteins utilizing the cytoskeleton as the railway for their movement 
fall into two categories: Actin motors, such as myosin, move along microfilaments through 
interaction with actin; Microtubule motors, such as dynein and kinesin, move along microtubules 
through interaction with tubulin. There are two basic types of microtubule motors: plus end- 
motors and minus end-directed motors, depending on the direction in which they "walk" along 
the microtubule cables within the cell. Motor proteins utilize ATP hydrolysis to generate the 
power they use to “walk”, which causes a small conformational change in the global motor 
domain (Figure 2). 
Figure 2. Schematic rendition of the intramolecular communication within one 
motor domain of myosin (a), kinesin (b) and dynein (c), and translation into a 
conformational change that leads to movement. 
[From Schlwa, M et al. Nature 422, 759 (2003). Ref. 8] 
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 Motor proteins are involved in protein, organelle and vesicle transport in cells, and non-
motor domains and associated proteins play a key role in this process. The protein myosin plays 
important roles in the contraction of muscle fibers in animals. Kinesins and dyneins play 
essential roles in the formation of the mitotic spindle apparatus and the separation of 
chromosomes during mitosis and meiosis. Dynein is also found in flagella and is crucial for cell 
motility. 
Much effort has been expended in the pursuit of small molecule inhibitors of kinesins and 
myosins (Figure 3). In 1998, a small molecule known as adociasulfate-2 (AS-2), from the active 
extract of marine sponge, was found to disrupt microtubule attachment to the kinesin-coated 
surface in a motility assay and to completely inhibit the MT-stimulated kinesin ATPase activity 
with an IC50 of 2.7 µM9. Specificity tests with various ATPases showed that the only enzymes 
substantially inhibited by AS-2 were kinesin superfamily members. However, tests with cells in 
grown in culture demonstrated that AS-2 has no effect on the proliferation of HeLa cells. AS-2 
was then injected into early Drosophila embryos. Arrest of nuclear division was observed with 
high concentrations of AS-2, and some distinct abnormalities (e.g., spindles and MT asters 
without chromosomes, mats of unattached MTs, etc.) were found with lower concentrations.  
The small molecule monastrol is an example of a cell-permeable, kinesin-specific 
inhibitor10. It was identified from a phenotypic screen in which monastrol caused monoastral 
spindles in mitotic cells. Monastrol inhibits Eg5 (a mitotic kinesin)-driven microtubule motility 
with an IC50 of 14 µM and has no effect on the localization and organization of the Golgi 
apparatus or lysosomes. Monastrol has gained acceptance as a biological tool for studying the 
mitotic function of Eg-511. 
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There are also several known small-molecule inhibitors of myosin. For example, 
blebbistatin is a known myosin II inhibitor discovered from a high-throughput screening assay12. 
It inhibits both the ATP and gliding activities of human platelet non-muscle myosin II without 
inhibiting myosin light chain kinase. It also rapidly disrupts directed cell migration and 
cytokinesis in vertebrate cells. Addition of blebbistatin to dividing cells blocks furrow ingression 
within 5 min and is reversible.  It is also known that N-benzyl-p-toluene sulfonamide (BTS) 
inhibits the Ca2+-stimulated rabbit muscle myosin  
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Figure 3. Chemical structures of the kinesin inhibitors AS-2 and monastrol, and the 
myosin inhibitors blebbistatin and BTS. 
 
II S1 ATPase, and reversibly blocks gliding motility12. Although BTS does not compete for the 
nucleotide-binding site of myosin, it weakens myosin's interaction with F-actin. BTS reversibly 
suppresses force production in skeletal muscle fibres from rabbit and frog skin at micromolar 
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concentrations. The discovery of such motor protein inhibitors with high specificity and cell 
permeability suggests that motor proteins may be potential targets for therapeutic applications. 
There are, however, few cell-permeable, dynein-specific inhibitors. At the time this work 
began, the only known dynein inhibitors included the ATP analogues erythro-9-(2-hydroxy-3-
nonyl)adenine (EHNA) and 5’-adenylimidodiphosphate (AMP-PNP), the sulfhydryl-reactive 
agent N-ethylmaleimide (NEM) and the natural product purealin. Details on dynein inhibitors 
will be discussed in section 1.3.3. 
1.3 Dynein as a molecular target 
1.3.1 Cytoplasmic dynein 
Dyneins are molecular motor complexes (dynein+dynactin) that generate force toward 
the minus ends of MTs13.  There are approximately 15 forms of dynein found in vertebrates; 
most of them are “axonemal”, referring to their role in ciliary and flagellar movement. Only two 
forms are “cytoplasmic”: cytoplasmic dynein-1, initially discovered by Richard Vallee et al. as 
the microtubule-associated protein 1C (MAP1C)13, which is widely expressed in cells and is 
responsible for a surprising range of functions; and cytoplasmic dynein-2, which has a restricted 
distribution and a narrow range of functions14,15. 
Cytoplasmic dynein is a multisubunit protein complex composed of a heavy chain 
(DyHC) polypeptide of >500 kDa, which is responsible for ATPase and motor activities, and 
several intermediate chains (ICs), light intermediate chains (LICs) and light chains (LCs) that are 
responsible for subcellular localization, and recognizing and binding the various forms of 
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“cargo” carried by dynein. The dynein motor domain is a hexamer of six tandemly linked 
ATPase-associated diverse cellular activities (AAA) modules10,16,17. The first four AAA modules 
are centrally located in dynein and are well conserved in all dynein sequences. It has been shown 
that the AAA1 module contains the site of ATP hydrolysis that leads to movement18. The next 
three modules, AAA2-AAA4, bind to nucleotides with lower affinity, but this binding is 
important for the regulation of dynein function19. AAAs 1-4 all contain well preserved P-loop 
elements that are important in removal of the γ-phosphate of ATP during hydrolysis. The P-loop 
elements within AAAs 5 and 6 are degenerate and less likely to be functional, but they must be 
intact with the other AAA modules for the proper dynein ATPase function20. A substantial 
projection called the 'stalk' emerges between AAAs 4 and 5 and has a microtubule-binding site at 
its tip (Figure 4). 
 
Figure 4 ． Organization of the 
dynein motor domain.  
(A) Generic model of a dynein particle 
containing two heavy chains. (B) Map of the 
γ heavy chain (HC) from Chlamydomonas 
outer arm dynein indicating the six AAA 
domains (AAA1-AAA6), P-loops (P1-P6), the 
microtubule binding region and coiled-coil 
segments. Also illustrated is the section that in 
cytoplasmic dynein is involved in HC-HC and 
HC-IC interactions, the LC1-binding and the 
epitope recognized by conoclonal antibody 
12γB. (C) Model for the organization of an 
individual HC illustrating the heptameric 
structure of the head. [From King, SM J. Cell. 
Sci. 2000,113:2521, Ref.10] 
 
A speculative model for the dynein 
cross-bridge cycle is shown in Figure 521. In 
 7 
the figure, the six AAA modules are depicted as spheres and are numbered. The stalk is the green 
projection at the top of the motor, and the stem connected to P1 is in blue at the bottom. The 
microtubule surface is at the top of the figure. These elements are not drawn to scale. Figure 5a 
shows the relaxed conformation. The dynein is not attached to the microtubule. Binding of 
nucleotides to P1–P4 (to all modules or to some subset of modules) causes inter-module 
reorientation and results in the tilting of the stalk (Figure 5b). Dynein remains unattached to the 
microtubule. Hydrolysis of ATP at P1 results in a ‘cocking’ of the stem and the subsequent 
binding of the stalk to the microtubule (Figure 5c). Release of the ATP hydrolysis products from 
P1 results in a force-generating swinging of the neck domain and the net movement of the 
microtubule towards the right (Figure 5d). 
 
 
Figure 5. A speculative model for the dynein cross-bridge cycle.  
[From Asai, DJ et al. TRENDS in Cell Biol. 2001, 11:196, Ref 21] 
 
Electron microscopy was used to reveal a new model for the structure and mechanism of 
dynein c, an isoform of flagellar dynein22 (Figure 6). Six AAA domains and a C-terminal domain 
form a planar ring, with the stalk emerging between AAA4 and AAA5, and a hook-shaped stem 
joining AAA1. The conformation of stem and stalk in pre-power-stroke state (ADP·Vi) and post-
power-stroke state (Apo) was compared to examine the magnitude of the power stroke (Figure 
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6a). Alignment of their stems suggests a mean displacement of 15nm of the tip of the stalk. A 
change in head orientation may also contribute to the apparent (projected) size of this 
displacement. A linker domain was also found to connect stem and head. In the typical ADP·Vi 
molecule (Figure 6b, left), the docked linker occludes the central channel and the stem emerges 
from the head far from the stalk. Rigid coupling between AAA1 and linker causes a rolling of the 
head towards the stem, which translates the microtubule by 15nm under zero load conditions. 
The resulting movement of AAA2–4 towards the linker increases the prominence of the central 
channel (Figure 6b, right). Movement between AAA4 and AAA5 increases stalk stiffness by 
changing the structure of its junction with them. This result suggests that a change in the head-
linker orientation is fundamental in the power stroke of dynein. 
Figure 6. Structure and power stroke of dynein c.  
a, Left views of dynein c showing the mean conformation of the stem and stalk relative to the 
head. Images were made by compositing class averages having the mean stem and stalk angles. 
Images are shown after alignment of their stems. The arrow indicates 15 nm. b, Speculative 
structure of the molecule suggesting an origin of the power stroke and how this might be 
converted into microtubule movement. The six AAA modules (1–6) and C-terminal sequence 
(C) are indicated. The microtubule track (not drawn to scale) is illustrated as moving under zero 
load with its plus end leading. c, Molecule showing the stem undocked from the head. [From 
Burgess, SA et al. Nature 421, 715, 2003. Ref22] 
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1.3.2 The dynein transportation system 
Cytoplasmic dynein provides force towards the minus end of microtubules. It is involved 
in many fundamental cellular processes such as vesicular return to the MT organizing center, as 
well as the retention of the vesicles at this subcellular locale. Cytoplasmic dynein is intricately 
involved in the maintenance of the Golgi apparatus and the trafficking of membrane-
encapsulated vesicles and proteins such as membrane-bound receptors. Cytoplasmic dynein is 
also involved in mitosis, including nuclear envelope breakdown at late prometaphase, several 
aspects of chromosome segregation and helping to form the mitotic spindle. It is known that p53 
is associated with cellular microtubules and that dynein transports p53 to the nucleus23. P53 is a 
tumor-suppressor protein involved in cell-cycle control, apoptosis, differentiation, DNA repair 
and recombination, and centrosome duplication. Other examples of known cargoes and 
interaction proteins for the dynein include the proapoptotic Bcl-2 family member Bim24, 
dynactin, which links dynein to its cargo, Cdc2 kinase, which phosphorylates a light intermediate 
chain of dynein during mitosis, and the mineralocorticoid receptor. It is also known that 
cytoplasmic dynein and its associated proteins are related to many diseases such as retinitis 
pigmentosa25, lissencephaly26, virus transport27 and neurodegenerative diseases28. Several 
important known or potential drug targets interact with the cytosolic dynein complex at one or 
more points in their cellular lifetimes. Some examples include the tubulin deactylase HDAC629 
and the heat shock protein Hsp9030, 31. The latter may well be an important partner in dynein’s 
translocation of both hormone receptors and p53 protein to the microtubule organizing center at 
the nucleus. Galigniana et al.30, 31 have presented data in recent reports describing compelling 
models for the interactions between p53 with dynein via linkages provided by Hsp90, in concert 
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with Hsp70, to immunophilins bound to region of the dynactin-associated portion of the dynein 
complex that binds the inhibitor dynamitin (Figure 7). 
 
 
Figure 7. Model of links between cytosolic dynein heavy chain to p53.  
An immunophilin (IMM) links to p53-bound HSP90 through its tetratricopeptide repeat (TPR) 
domain (solid line). The IMM in turn links to the dynamitin (Dyt)-binding region of the dynein-
associated dynactin (Dyt) complex by means of its peptidyl-prolyl isomerase (PPIase) domain 
(dotted line). [From Galigniana et al., J.Biol.Chem. 2004, 279:22483. ref. 30.] 
 
Dynein also play roles in the transport of certain viruses into cells. By microinjecting 
function-blocking anti-dynein antibodies or overexpressing dynamitin, the role of dynein was 
established for the efficient nuclear targeting of herpes simplex virus (HSV)32, adenovirus 
(Ad)33,34 or canine parvovirus (CPV) capsids35, HIV reverse transcription complexes36 and 
influenza virus37. It is also known that incoming HSV capsids colocalize with dynein and 
dynactin27,32, and also that Ad38, in addition to CPV capsids35, can interact with dynein and MT 
in vitro. 
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1.3.3 Known dynein inhibitors 
Very little is known about dynein inhibitors (Figure 8). It is known that AMP-PNP, a 
ATP mimic, inhibits dynein’s ATPase activity39. The sulfhydryl-reactive agent NEM has also 
been reported to interact with dynein ATPase40. EHNA inhibits axonemal dynein ATPase 
activity. It acts as a mixed inhibitor of both the axonemal dynein ATPase activity and of partially 
purified dynein 1 ATPase activity41. EHNA has little effect on either the myosin or the Na+,K+-
ATPase. The only known non-ATP mimic, non-sulfhydryl reactive dynein inhibitor is the natural 
product purealin, which is be discussed in section 1.3.4. Purealin served as the starting point of 
this work in the search for dynein-specific, cell-permeable inhibitors. None of the dynein 
inhibitors known at the beginning of this work are specific for dynein motor. 
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Figure 8. Chemical structures of the known dynein inhibitors EHNA, AMP-PNP 
and NEM. 
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1.3.4 Purealin and purealin library 
Purealin is a novel agent isolated from the sea sponge Psammaplysilla purea42. It 
selectively inhibits the ATPase activity of isolated dynein and myosin without competing for the 
ATP site on the motor proteins43,44. Other small molecules that can inhibit dynein includes 
vanadate anion, some ATP analogs, and thiol-perturbing agents since dynein has a thioredoxin-
like domain including vicinal thiols10. The structure of the only known non-ATP-mimicking 
dynein inhibitor, purealin, and other related dibromotyrosine-derived natural products are shown 
in Figure 9. Many of the compounds consist of a center dibromotyrosine unit attached on the 
right to a side chain via an amide bond and attached to the left through a three-carbon spacer and 
another amide bond to a second dibromotyrosine ring. 
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Figure 9. Structures of the only known non-ATP-mimicking dynein inhibitor, 
purealin, and other related dibromotyrosine-derived natural products. 
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In the last two decades, a series of publications report the isolation and structure 
elucidation of  bromotyrosine-derived alkaloids, including purealin45, purealidin A26, 
lipopurealins A, B and C46 (Figure 10). Common structures of these compounds include the 
bromotyrosine unit with the aminohistamine moiety. In purealin, the spiroisoxazoline as a side 
chain is coupled to the bromotyrosine amine; in lipopurealin A, B and C, fatty acids side chains 
are coupled with the bromotyrosine amine. 
Purealidin A has weak inhibitory activity (22% inhibition at 100 µM) against Na+,K+-
ATPase and exhibits some cytotoxicity against L1210 murine leukemia cells with a reported IC50 
value of 1.1 µg/mL. Lipopurealins A,  B and  C exhibit inhibitory activities on Na+,K+-ATPase 
purified from porcine brain and dog kidney, with lipopurealin B being the most potent 
inhibitor46. 
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Figure 10. Bromotyrosine-derived alkaloids.  
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Since purealin is active against ATPase activity of axonamal dynein, the first hypothesis 
tested was that purealin, and perhaps its analogues, also inhibit cytoplasmic dynein ATPase 
activity, as well as cell proliferation. Therefore, purealin and the twenty synthetic purealidins 
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were prepared by Dr. Fanglong Yang in Prof. Curran’s lab. These compounds (Figure 11) 
compose the first library examined in biological assays. 
1.4 Hsp70 as a chemotherapeutic target 
1.4.1 Hsp70 as a molecular chaperone 
Molecular chaperones are a family of proteins which help a protein search for and anchor 
cellular partners, as well as provide force or anchoring points for the subsequent rearrangement 
or dissolution of muti-protein complexes. Molecular chaperones are generally up-regulated by 
heat shock or stress (e.g., glucose deprivation), and the heat shock proteins (Hsps) and glucose 
responsive proteins (Grps) uncovered from studies in mammalian cells were named based on the 
shock found to cause their upregulation, followed by their molecular masses. For example, 
Hsp70s are the heat shock proteins of molecular mass of ca. 70 kDa13. It is also known that 
several bacterial molecular chaperones, including DnaK and DnaJ, play essential roles in 
bacteriophage DNA replication in E. coli and that Hsp70/DnaK and Hsp40/DnaJ are actually two 
highly conserved and abundant chaperone families. In addition, heat shock “cognate” proteins 
(Hscs) are Hsp homologues that play vital housekeeping roles by catalyzing protein folding, 
assembly, degradation, and transport. Hsc70 and Hsp70 generally exhibit identical biochemical 
activities and are highly conserved. 
Hsp/Hsc70 chaperones contain three independent domains, a highly conserved 44-kDa 
N-terminal ATPase domain and an 18-kDa peptide binding domain and a 10-kDa C-terminal 
helical lid domain47. The helical lid gates the peptide substrates in an elongated channel and 
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ATP-binding to the ATPase domain opens the lid, resulting in a weaker affinity for peptide 
substrates48. Transient interactions with peptides stimulate Hsp70 ATP hydrolysis, resulting in a 
conformational change in the chaperone wherein the lid closes to capture peptide substrates. 
Hsp40s act as co-chaperones of Hsp70 and stimulate the ATPase activity of Hsp70s and stabilize 
the Hsp70-peptide complex. Hsp40 contains a ~70-amino acid “J domain” that interacts with the 
ATPase domain of Hsp7049. 
Hsp70 and Hsp40 co-chaperone are related to many human diseases. For example, they 
are a therapeutic target for the symptoms of cystic fibrosis caused by protein folding defects50, 51. 
Hsp70 and Hsp40 also contribute to tumorigenesis52,53. Several unique tumor types exhibit 
elevated expression of these chaperones, and overexpression of Hsp70 alone can lead to cellular 
transformation and tumorigenesis54,55. It is known that inhibition of Hsp70 synthesis by antisense 
(as) Hsp70 cDNA induces massive death of breast cancer cells56. The asHsp70-induced death is 
independent of known caspases and the p53 tumor suppressor protein. In addition, Bcl-2 and 
Bcl-XL fail to rescue breast cancer cells from asHsp70-induced cell death.  It is also known that 
some viral oncogenes recruit cellular Hsp70 to inactive growth control checkpoints57. The large 
T antigen (Tag) of the DNA tumor virus, simian virus 40 (SV40), contains a J domain that 
stimulates Hsp70 to rearrange multiprotein complexes involved in cell cycle regulation57. 
Therefore, Hsp70 modulators could serve as chemotherapeutic agents. 
Hsp70 protects tumor cells from apoptosis (for a review, see ref.58 ) Although Hsp70 is 
induced upon cellular stress to prevent protein aggregation and facilitate protein refolding or 
disposal, it also protects cells from a wide range of apoptotic pathways. It is known that Hsp70 
inhibits key effectors of the apoptotic machinery, including the apoptosome, the caspase 
activation complex, and apoptosis-inducing factor (AIF)58. Hsp70 facilitates the proteasome-
 17 
mediated degradation of apoptosis-regulatory proteins. Hsp70 also inhibits the stress-activated 
Jun N-terminal kinase (JNK), which is an apoptosis inducer though a caspase-independent 
pathway, the release of cytochrome (cyt) c and AIF from mitochondria, and the activation of 
Apaf-1 and caspase 3,959,60. 
1.4.2 Compounds targeting Hsp70 
Although Hsp70 plays very important roles and is related to human cancer and other 
diseases, very few Hsp70 modulators have been identified. One compound, 15-deoxyspergualin 
(DSG), binds specifically to Hsp70 with a Kd of ~ 4µM and stimulates its steady-state ATPase 
activity by 20~40%, but has no effect on peptide binding nor Hsp40 activation of Hsp70 ATPase 
activity61-63. It has been shown in vitro to modestly facilitate the trafficking of ΔF508-CFTR to 
the plasma membrane64. DSG has already been in Phase II trial as an immune-suppressant for 
kidney transplant patients40. However, DSG also binds Hsp90 with a Kd of ~ 5µM62. Therefore, 
DSG may function through its action on Hsp90 along with its binding to Hsp70. 
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Another class of Hsp/Hsc 70 modulator are the 3’-sulfogalactolipid (SGLs), including 
sulfogalactosylceramide (SGC), sulfogalactoglycerolipid (SGG) and adamantylSGC (adaSGC). 
SGLs bind to the ATPase domain of Hsc70 and inhibit its endogenous and Hsp40-stimulated 
steady-state ATPase cycle65,66. In addition, adaSGC inhibits Hsc70/SGL binding and behaves as 
a noncompetitive inhibitor of Hsc70 ATPase activity66. There is no report on the cellular actions 
of SGL compounds so far. However, I did work that showed adaSGC does not signifiantly alter 
the proliferation of the human breast cancer cell SK-BR3. 
NSC-630668-R/1 (R/1) is another example of Hsp70 modulator. Its actions in this regard 
were discovered by the Day and Brodsky groups at the University of Pittsburgh67. It was selected 
from an in silico screen of DSG structural analogues in the National Cancer Institute’s (NCI) 
Developmental Therapeutics Program. R/1 was found to inhibit the steady-state ATPase activity 
of yeast Hsc70 and to block the Hsc70-mediated translocation of a preprotein into yeast 
endoplasmic reticulum (ER)-derived microsomal vesicles. In their initial report, the Day/Brodsky 
collaborators also claimed that DSG and R/1 modulate Hsc70 activity by distinct mechanisms. 
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Figure 13. (A) Chemical structure of MAL3-101 and (B) superimposed molecular 
models of R/1 (yellow) and MAL3-101 (white).  
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Based on the initial findings, several dihydropyrimidines, synthesized from Biginelli and 
Ugi reactions by Prof. Wipf’s group, were also found to interact with Hsp70. Computational 
conformational analysis showed one of the compounds, MAL3-101, can adopt a conformation 
very similar to that of R/1 compound (Figure 13). In a single turnover Hsp70 ATPase assay, 
MAL3-101 inhibits TAg-stimulated Hsp70 ATPase activity in a concentration-dependent way, 
without disturbing the ATPase activity of TAg. MAL3-101 served as the starting point for the 
search for more potent, Hsp70-specific inhibitors, with desired cellular properties. 
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2.0  MATERIALS AND EXPERIMENTAL PROCEDURES 
2.1 Materials 
RPMI 1640 medium, penicillin-streptomycin, L-glutamine, lipofectamine and trypsin-
EDTA were obtained from Invitrogen Co., Carlsbad, CA. Fetal bovine serum (FBS) was 
obtained from Hyclone, Logan, UT. 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) and 37% formaldehyde were obtained from Fisher Co., Fairlawn, NJ. Piperazine-N,N'-
bis(2-ethanesulfonic acid) (PIPES), adenosine triphosphate (ATP), guanosine triphosphate 
(GTP), 2-(morpholin-4-yl)ethanesulfonic acid (Mes), monosodium glutamate (MSG) and sucrose 
were obtained from USB Co., Cleveland, OH.  MgCl2, KCl, ethylenediaminetetraacetitic acid 
(EDTA), dimethylsulfoxide (DMSO), erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), sodium 
citrate, ethyleneglycoltetraacetic acid (EGTA), phenylmethylsufonyl fluoride (PMSF), trypan 
blue solution (0.4%), dulbecco's modified eagle's medium (DMEM), anti-dynein intermediate 
chain antibody, 2-Mercaptoethanol, α-cyano-4-hydroxycinnamic acid (CHCA), bovine collagen-
I, Hoechst 33342, ammonium bicarbonate and formic acid were from Sigma Co., St.Louis, MO. 
Tris(hydroxymethyl)aminomethane (Tris), Coomassie G250 stain, Tween-20, polyvinylidene 
difluoride (PVDF) membrane, triton X-100, glycine and SDS were obtained from Bio-Rad 
Laboratories  Inc., Hercules,  CA. Dithiothreitol (DTT) was from Boehringer Ingelheim Inc., 
Ridgefield, CT. Paclitaxel was from the NIH Drug Synthesis Branch. ProtoGel 30% (w/v) 
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acrylamide:0.8%(w/v) bis-acrylamide stock solution was from National Diagnostics, Atlanta, 
GA. Malachite green and HCl were from J.T.Baker Co., Phillipsburg, NJ. Rabbit anti-dynein 
heavy chain polyclonal IgG was purchased from Santa Cruz Biotechnology  Inc., Santa Cruz, 
CA. Acetonitrile was obtained from Fisher Co., Fairlawn NJ. Trypsin for in-gel tryptic digestions 
was sequencing grade modified trypsin from Promega Co., Madison, WI Mouse anti-α-tubulin 
antibody was from NeoMarkers/Lab Vision Inc. Fremont, CA. Sheep anti-p53 antibody was 
from Calbiochem Inc., Sandiego, CA. Cy5-labeled donkey anti-sheep and cy3-labeled donkey 
anti-mouse antibodies were from Jackson ImmunoResearch Laboratories Inc., West Grove, PA. 
Lipofectamine. Opti-MEM. etc. [32P]ATP was from PerkinElmer Inc., Waltham, MA. Rabbit 
skeletal muscle myosin II was from Cytoskeleton Inc., Denver, CO. Dynein heavy chain siRNA 
and negative control siRNA were obtained from Ambion Inc, Austin, TX. Tubulin was purified 
in the Day lab by the method of Hamel, E. and Lin, C.M., ref 68. 
2.2 Experimental procedures 
2.2.1 Antiproliferative assay 
Cells were grown in RPMI 1640 medium with 10% FBS.  Human epithelial cancer cells 
(MDA-MB231 breast, PC-3 prostate, 2008 ovary and HT-29 colon) were trypsinized and plated 
into 96-well microtiter plates at 500-2000 cells/well (depending on the cell line) in 96-well 
plates, allowed to attach and grow for 72h, then treated with vehicle (DMSO) or test agent for an 
additional 72h. For the mouse leukemia L1210 line, cells were plated into 96-well plates at 7500 
cells/well and treated with test agents, incubated for 48 h. In each case, one plate consisted 
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entirely of wells containing cells in medium and wells with medium alone to determine time zero 
time cell numbers. The other plates in a given determination contained eight wells of control 
cells, eight wells of medium, and each test agent concentration in quadruplicate. Cell viability 
was determined with the MTS assay and 50% growth inhibitory concentrations (GI50) were 
determined. Discodermolide (DCD) was used as a positive control in all the assays. 
2.2.2 Dynein purification from bovine brain 
Extraction buffer (50mM HEPES + 50mM PIPES, pH 7.0, containing 2mM MgCl2 and 
1mM EDTA), Tris-KCl buffer (20mM Tris-KCl, pH 7.6, containing 50mM KCl, 5mM MgCl2 
and 0.5mM EDTA) were prepared. Fresh bovine brain (obtained free of charge from a local 
slaughterhouse) was homogenized in a blender at 4 ºC in one volume of extraction buffer. The 
mixture was centrifuged in a JA-18 rotor at 6,000rpm for 30min and kept at 4 oC. The 
supernatant was recovered and further centrifuged in a Ti45 rotor at 28,000rpm for 60min at 4 oC 
to obtain a clean cytosolic extract. Paclitaxel (20µM) was added to this extract and the mixture 
was incubated at 37 oC for 15min to polymerize tubulin. The mixture was centrifuged in a 
JA30.50 rotor at 18,600rpm for 30min in the presence of 7% sucrose in extraction buffer. The 
pellet was resuspended in extraction buffer and paclitaxel (5µM) was added. The mixture was 
incubated at 37 oC for 15min to form MTs. The mixture was centrifuged in a Ti70.1 rotor at 
23,000rpm for 30min at 30 oC. The MT pellet was resuspends in extraction buffer and 3mM GTP 
along with 5µM paclitaxel were added. The mixture was incubated at 37 oC for 15min and 
spinned in a Ti70.1 rotor at 23,000rpm for 30min at 20 oC. The pellet was resuspended in 
extraction buffer and ATP (10mM) was added. The mixture was incubated at 37 ºC for 12min to 
release cytoplasmic dynein. The mixture was further centrifuged in a Ti70.1 rotor at 30,000rpm 
 23 
at 20 ºC for 30. The supernatant was fractionated using 5-20% sucrose gradient (prepared in 
Tris-KCl buffer) in a SW41 rotor at 27,000rpm for 16h at 4 ºC. Protein content in the fractions 
was estimated with the Bio-Rad protein reagent. Aliquots of the sucrose gradient gradient 
fractions were analyzed on 6.5% polyacrylamide SDS-PAGE gels after staining with Coomassie 
blue. 
2.2.3 Glycerol-based dynein purification 
A homogenization buffer was prepared. Extraction buffer and Tris-KCl buffer were 
prepared as mentioned before. The fresh brain was homogenized in a blender at 4 ºC in one 
volume of extraction buffer (100mM PIPES, pH 6.9-7.2, containing 5mM MgCl2, 1mM EGTA 
and 1mM PMSF), and the homogenate was centrifuged in a GSA rotor at 10,000rpm for 20min. 
The supernatant was obtained and adjusted to 1.0mM GTP. The mixture was centrifuged in a 
45Ti rotor at 40,000rpm for 60min. Glycerol was added to the supernatant at a final 
concentration 2.74M. The mixture was incubated at 34-37 oC for 45min for the microtubule 
assembly, then was further centrifuged in 45Ti rotor at 40k rpm for 60min. The pellet was 
resuspended in the homogenization buffer in the presence of 0.5mM GTP and was incubated on 
ice for 30min. After another ultracentrifugation in a 70Ti rotor at 40,000rpm for 40min, the 
supernatant was adjusted to 2.74M glycerol and incubated again at 34-37 oC for 45min. The 
mixture was untracentrifuged, the pellet was resuspended, and 3mM GTP with 20uM paclitaxel 
were added to the solution, which incubated for 15min at 37 oC. After a centrifugation at 18k in a 
JA30.50 rotor for 20min, the pellets were resuspended in the extraction buffer and 20mM ATP 
was added to the solution for another incubation for 20min at 37 oC. After high speed 
centrifugation at 45k rpm, the mixture was fractionated using a 5-20% sucrose gradient (prepared 
 24 
in Tris-KCl buffer) in a SW41 rotor at 27,000rpm for 16h. Aliquots of the sucrose gradient 
gradient fractions were analyzed on 6.5% polyacrylamide SDS-PAGE gels after staining with 
Coomassie blue. 
2.2.4 Colorimetric ATPase assay 
Malachite green (340 mg) was dissolved in 75 mL of water.  Ammonium molybdate 
(10.5 g) was dissolved in a mixture of 83 mL of 37% HCl and 167 mL of water.  The two 
solutions were mixed and water was added to give a final volume of 1 L.  The solution was 
stored at 4oC for no more than 1 month.   A 1:250 volume of 10% Tween-20 was added just 
before using the malachite green solution.  Paclitaxel-induced MTs, dynein heavy chain 
(20ug/mL final concentration) and the negative control (DMSO only) or the EHNA solution, 
were premixed in reaction buffer (the Tris-KCl buffer used in the dynein preparation work). The 
reaction mixture was incubated at 37ºC for 30min. Per 100µL of reaction mixture, 800 µL  
malachite green solution and 100 µL 34% aqueous sodium citrate were added and the 
absorbance at 655nm was determined in a 96-well microtiter plate reader. The amount of free 
phosphate released by dynein heavy chain was calculated from a sodium phosphate standard 
curve. 
2.2.5 Western blotting 
Proteins were transferred from SDS-PAGE gels to PVDF (Bio-Rad) membranes using a 
Bio-Rad Trans-Blot Semi-Dry transfer system for 1.5h in 25mM Tris, pH 7.0, containing 19mM 
glycine and 20% methanol. Membranes were washed in 50 mM Tris buffer, pH 7.4, containing 
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0.5M NaCl and 0.1% (v/v) Tween 20, and then blocked using the Amersham Western Blotting 
blocking agent. Rabbit anti-dynein heavy chain polyclonal IgG (1:500 dilution) was added to the 
blocking buffer and the membrane was incubated at 4oC overnight.  The membrane was washed, 
blocked once again, and anti-rabbit antibody (1:5000 dilution) was added.  The Amersham ECL 
chemiluminescence system and Fuji film were used to detect the protein bands. 
2.2.6 SDS-PAGE 
Purified bovine cytoplasmic dynein (1.6 µg per well) was loaded into a 6.5% SDS-PAGE 
gel. A Tris-glycine buffer (Tris 6g/L, glycine 28.8 g/L, SDS 1 g/L) was used to run the gel. Gels 
were then washed in clean water and stained with Coomassie blue for 1 h. 
2.2.7 In-gel digestion with trypsin 
After visualization, the bands of interest were excised from the SDS-PAGE gels and 
soaked in 1:1 CH3CN-25mM aq. NH4HCO3, pH 7.8, for 10 min with vortex mixing for full 
destaining. The supernatant was removed and the destaining process was repeated three times. 
The gel pieces were then completely dried in a SpeedVac lyophilizer. Enough aq. 25mM 
NH4HCO3, pH 7.8, containing 10mM dithiothreitol (DTT) was added to cover each individual 
gel piece and the mixtures were incubated at 56 ºC for 1 h to reduce disulfide bonds. The 
supernatant was removed and 25mM NH4HCO3, pH 7.8, containing 50 nM iodoacetamide was 
added to carbamidomethylate sulfhydryl groups. The mixture was incubated in the dark for 45 
min at room temperature. The supernatant was removed and 25mM NH4HCO3, pH 7.8, was 
added. After 10 min of vortex mixing, the supernatant was removed and the gel plugs were 
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soaked in 1:1 CH3CN-25mM aq. NH4HCO3, pH 7.8, for 5 min with vortex mixing. 
Subsequently, the gel pieces were completely dried in a SpeedVac. 
Tryptic digestion was performed via the addition of 20 µL of 20 ng/µL trypsin in 20mM 
aq. NH4HCO3, pH 7.8, and incubation for 14h at 37 ºC without agitation. The digestion was 
stopped by the addition of 100 µL of H2O. The peptides were extracted into 1:1 CH3CN-H2O 
containing 5% HCO2H and the extract was taken to complete dryness in a SpeedVac. 
2.2.8 Mass spectrometry 
The dried samples were resuspended in 10 µL of 1:1 CH3CN-H2O containing 0.1% 
CF3CO2H. Then, 1 uL of the sample solution was mixed with 3 µL of 1:1 CH3CN-H2O 
containing 0.1% CF3CO2H and 6 uL of 1:1 CH3CN-H2O containing 0.1% CF3CO2H and 
saturated with α-cyano-4-hydroxycinnamic acid (CHCA). Subsequently, aliquots of 0.5 µL were 
applied to a stainless steel target and allowed to air dry. MALDI-TOF and MALDI-TOF/TOF 
mass spectra were recorded with an Applied Biosystem 4700 Proteomics Analyzer in the 
reflectron, positive ion detection mode. 
2.2.9 Dynein ATPase inhibition assay 
The ability of the purealin analogues to inhibit the ATPase activity of cytoplasmic dynein 
heavy chain was determined as follows. A colorimetric assay to measure inorganic phosphate 
release (malachite green assay) was used. With the malachite green detection system, paclitaxel-
induced MTs (1mg/mL final concentration based on soluble tubulin incubated with 10µM 
pacitaxel), dynein heavy chain (20µg/mL final concentration) and the test agents (50, 10, 2, 0.4 
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and 0.08µM), as well as the positive control (EHNA, an adenosine analogue known to inhibit 
dynein ATPase activity, 5mM final concentration) and the negative control (DMSO only), were 
premixed in reaction buffer (20mM Tris-KCl, pH 7.6, containing 50 mM KCl, 5 mM MgCl2 and 
0.5mM EDTA). ATP (2mM) was added to initiate the reaction. The other controls, including a 
no enzyme control (all but dynein heavy chain), a no substrate control (all but ATP) and a no 
enzyme/substrate control (all but ATP and dynein heavy chain) were also prepared. The reaction 
mixture (100µL) was incubated at 37ºC for 30min. The malachite green solution (1mM 
malachite green, 8.5mM ammonium molybdate and 0.8M HCl, 100µL) and 34% aqueous 
sodium citrate solution (100µL) were added and the absorbance at 655nm was determined in a 
96-well microtiter plate reader. The absorbance values determined from the controls were 
subtracted from the absorbance values of the full reaction. The amount of free phosphate 
released by dynein heavy chain was calculated from a sodium phosphate standard curve. The 
percentage of control was calculated from the ratio of the ATPase activity of dynein heavy chain 
with a specific concentration of an inhibitor and the ATPase activity of dynein heavy chain only 
(results are given in Figure 27 and Table 8). 
 
2.2.10 P53 nuclear translocation assay 
A549 lung cancer cells were cultured in RPMI 1640 medium plus 10% FBS and 0.1% 
penicillin/streptomycin. Slides/plates were first cleaned with 70% ethanol, allowed to air dry, 
and then coated with 0.25mg/mL bovine collagen-I in 0.1% acetic acid (freshly made) and dried 
in the hood overnight. Log phase growth cells were plated on the collagen-coated slides/plates 
and incubated for 48h at 37°C in a humidified, 5% CO2 atmosphere. The cells were incubated in 
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the presence of compounds for 20h. At the end of an experiment, the solution was removed from 
the microplates/slides and immediately replaced with a solution of HBSS containing 4% 
formaldehyde and 10μg/mL Hoechst 33342 to fix the cells and fluorescently label their nuclei. 
After incubation at room temperature for 20 to 30 min, the solution was removed and replaced 
with Hank’s balanced salts solution (HBSS) (100 μL/well). At this point, microplates could be 
sealed and stored at 4°C overnight. After removing the HBSS from each well, 0.5% (w/w) Triton 
X-100 was added and the plate was incubated for 5 min at room temperature to detergent-extract 
a fraction of the soluble cellular components, including soluble tubulin. The wells were then 
washed with HBSS (100 μL/well) followed by the addition of a primary antibody solution 
containing mouse anti-α-tubulin (NeoMarkers, 1:1000) and sheep anti-p53 (CALBIOCHEM, 
1:500) in HBSS. After 1h of incubation at room temperature, the samples were washed with 
HBSS as above, followed by the addition of a secondary antibody solution containing Cy5-
labeled donkey anti-sheep (Jackson ImmunoResearch, 1:500) and Cy3-labeled donkey anti-
mouse (Jackson ImmunoResearch, 1:1000) antibodies diluted in HBSS. After a 1h incubation at 
room temperature, the samples were washed as above and HBSS was added (100 μL/well) before 
sealing the microplates/slides. Labeled microplates could be stored at 4 °C for up to 2 weeks 
before high-content analysis. 
2.2.11 Dynein heavy chain siRNA experiment 
Dynein heavy chain siRNA #1, 2, 3 were obtained from Ambion Inc (for sequences, see 
Table 6). A negative control siRNA was also obtained which is a 19bp scrambled sequence with 
3’ dT overhands and the sequence have no significant homology to any know gene sequences 
from mouse, rat or human.. Eight-well chamber slides were coated as described above with 
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0.25mg/mL collagen-I in 0.1% acetic acid (100μL/well) and dried in the hood for around 6 h. 
A549 cells were resuspended in RPMI 1640 medium with 10% FBS without antibiotics and 
plated in the 8-well chamber slides at 2,000 cells per well. Cells were allowed to attach for at 
least 24 h before transfection. On the day of transfection, for each well, 0.375 μL lipofectamine 
was gently mixed with 12.5 μL Opti-MEM and incubated at room temperature for 5min to obtain 
the lipofectamine mixture. A solution (50nM or 150nM) of the negative siRNA (0.375 µL) was 
gently mixed with 12.5 μL of Opti-MEM to give the negative siRNA mixture. 0.75 μL siRNA (1, 
2, 3 or mixtures thereof) was gently mixed with 12.5 μL of Opti-MEM to give the siRNA 
mixture. The lipofectamine mixture was mixed with the negative siRNA mixture or siRNA 
mixture and incubated at room temperature for 15 min. Growth medium was removed from the 
culture well and cells were washed with Opti-MEM for three times. Lipofectamine-siRNA 
mixture was added to cell culture and incubated at 37 ºC for 4 h. Opti-MEM medium with 30%  
serum was added and incubated at 37 ºC.  After 48 h, cells were detached by trypsinization, 
washed with HBSS, then lysed in 0.1M 2-(morpholin-4-yl)ethanesulfonic acid (Mes), pH 6.75, 
containing 0.1% Triton X-100, 1 mM MgSO4, 2 mM EGTA and 4 M glycerol. The lysate was 
centrifuged at 14,000 rpm in an Eppendorf microcentrifuge. The supernatant was boiled in 
loading buffer, loaded onto 10% polyacrylamide gels, and separated by electrophoresis. Proteins 
were transferred to polyvinyldifluoride membranes (Biorad), using a Biorad Transblot Semidry 
system. After washing, blocking, and treating with appropriate antibodies, protein bands were 
detected using the Amersham ECL Western blotting system and Fuji film. Densitometric 
analyses were performed with ImageJ (v. 1.32j) software. 
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2.2.12 GFP-glucocorticoid receptor nuclear translocation assay 
Mouse mammary adenocarcinoma cells 3617.4 (a kind gift from Prof. Gordon Hager, 
University of Michigan) stably expressing GFP-rat glucocorticoid receptor (GR)69 under control 
of the “Tet-Off” inducible system were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% FBS and 10 µg/mL tetracycline at 37 ºC under a 5% CO2, 
humidified atmosphere. Cells were plated at 6000 cells/well in a 96-well plate. At the time of 
transfer, the medium was replaced with DMEM without tetracycline to induce GFP-GR 
expression. Wells were then treated with the test agents (100µM), controls (vide infra), as well as 
vehicle (DMSO) only. To trigger GFP-GR translocation to the nucleus, cells were incubated for 
15 min with 1 µM dexamethasone or its vehicle (ethanol – negative control). The medium was 
then removed and cells were washed three times with phosphate buffered saline (PBS). Cells 
were fixed and permeabilized by immersion in cold methanol (–20ºC) for 20 min. Hoechst 33342 
(10 µg/mL) was added to fluorescently label nuclei. Mouse anti-α-tubulin (NeoMarkers, 1:1000) 
and Cy3 donkey anti-mouse (Jackson ImmunoResearch, 1:1000) antibodies were also used in 
some cases to fluorescently label microtubules. Cells were photographed with a Leica DC300F 
fluorescent microscope or an Olympus IX70 inverted microscope. Cells within images were then 
scored for GFP-GR nuclear translocation using a system published previously70, wherein a score 
of 4 was given for nuclear fluorescence much greater than cytoplasmic fluorescence, 3 for 
nuclear fluorescence greater than cytoplasmic fluorescence, 2 for nuclear fluorescence equal to 
cytoplasmic fluorescence, 1 for nuclear fluorescence less than cytoplasmic fluorescence, and 0 
for nuclear fluorescence much less than cytoplasmic fluorescence. The translocation scores 
reported represent the means ± S.E. from three different areas in an experiment, in which ≥ 30 
cells/area were counted. 
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2.2.13 Glucocorticoid receptor ligand binding domain competitor assay 
The GR competitor assay (Panvera) was performed according to manufacturer’s 
recommendations with some modifications. Recombinant human GR was used at the 
recommended concentration of 16nM and the supplied fluorescently labeled glucocorticoid 
ligand (FluormoneTM GS1) was used at 4nM in the final mixture. Recombinant human GR 
complexed with GS1 was distributed to all wells and then serial dilutions of test agents were 
added. DMSO content was kept at 1%. The required volumes of 4× concentration of GR and 4× 
concentration of GS1 were prepared on ice. GR and GS1 were then mixed together and 
distributed at 20 µL/well in square and black-bottom 384-well plates (Costar). Test agent 
dilutions, prepared in the screening buffer, were added at 20 µL/well. Dexamethasone was used 
as a standard. The plate was incubated at room temperature, protected from light, on a plate 
shaker for 2h. After incubation, the fluorescence polarization was measured using an AnalystTM 
AD &HT Assay Detection Systems reader (Molecular Devices) equipped with 485 nm excitation 
and 530 nm emission interference filters with the appropriate FL505 dichroic mirror. The 
instrumental set up was validated using serial dilutions (100nM to 1pM) of methylfluorescein 
(Sigma) in the screening buffer. Data were analyzed using GraphPad Prism’s one site 
competition method (Fig ). 
2.2.14 In vitro glucocorticoid receptor binding assay 
3617.4 cells were plated in 100 mm culture dishes in DMEM high glucose supplemented 
with 10% charcoal-stripped FBS and 10 µg/mL tetracycline and grown to confluence. Cells were 
then harvested by scraping into Hank’s buffered saline solution and centrifugation. The cell 
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pellet was resuspended in six volumes (compared to the packed cell volume) of lysis buffer (20 
mM Tris-HCl, pH 7.5, containing 50 mM NaCl, 1 mM EDTA, 5 mM dithiothreitol, 20 mM 
sodium molybdate and 10% glycerol). Cells were lysed by three cycles of freeze-thawing. Cell 
lysates were first centrifuged at 20,000 × g at 4ºC for 20 min and then at 100,000×g at 4 ºC for 
30 min. The supernatant, referred to as “cytosol”, was collected and stored at –80 ºC. For 
cytosols to be assayed for hormone binding, 75 µL of cytosol was incubated at 4 ºC for 2 h with 
25 nM [3H]dexamethasone (75nCi,  40Ci/mmol) in the presence of 1% DMSO (positive control), 
test agents or a 5,000-fold excess of non-radioactive dexamethasone (background). Samples 
were mixed with a suspension of activated charcoal (100 mg/mL in lysis buffer) and incubated 
for 20 min on ice. Samples were centrifuged and radioactivity in metered aliquots of the 
supernatant was determined by liquid scintillation spectrometry. The percent specific binding 
was calculated from the ratio of the specific binding of a test agent and the specific binding of 
the positive control. 
2.2.15 Recombinant cytoplasmic dynein motor domain expression and purification 
The 380-kDa motor domain fragment was cloned from Gly1286–Glu4644 of rat 
cytoplasmic dynein into the baculovirus expression vector pVL1393 (BD Biosciences) with a C-
terminal in-frame hexahistidine tag71. Hi5 cells were maintained at 26 ºC no CO2 in Express Five 
SFM medium (GIBCO) supplemented with L-glutamine (GIBCO). Hi5 cells were infected with 
virus for 40 h. The cells were washed and resuspended in PBS, and the recombinant motor 
domain fragments were extracted from the cells by homogenization in lysis buffer (20mM 
Hepes, pH 7.0, containing 50mM NaCl, 2mM MgSO4, 0.5 mM EGTA, 10mM imidazole and 1 
mM DTT) supplemented with protease inhibitor (Sigma) and 1mM ATP. The cytosolic extract 
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was spun at 5000×g for 10 min at 4 ºC and 100,000×g for 30 min at 4 ºC. The supernatant was 
applied to a Ni2+-affinity column (Ni2+-nitrilotriacetic acid superflow; Qiagen) equilibrated in 
lysis buffer. Unbound material was removed by washing with 10 volumes of washing buffer 
(20mM Hepes, pH 7.0, containing 350mM NaCl, 2mM MgSO4, 0.5mM EGTA and 30mM 
imidazole), and the protein was eluted in 6 volumes of elution buffer (20mM Hepes, pH 7.0, 
containing 50mM NaCl, 2mM MgSO4, 0.5 mM EGTA and 250mM imidazole). Protein 
concentration was determined by the Bradford method, using albumin as a standard. A typical 
batch of six 15-cm dishes of confluent Hi5 cells produced 2–4 mg of recombinant protein that 
had no visible sign of contaminants or degradation. Peak fractions were pooled, flash-frozen in 
liquid nitrogen, and subsequently stored at –80 ºC. 
2.2.16 Kinetics of cytoplasmic dynein heavy chain motor domain inhibition 
Motor domain (21.25 µg/mL final concentration) was premixed with the test agents in 10 
mM HEPES/10 mM PIPES, pH 7.0, containing 0.4 mM MgSO4 and 0.2 mM EDTA. Different 
concentrations of ATP (250, 125, 62.5, 31.3 and 15.6 µM) were added to the system to initiate 
the reaction. The mixtures were incubated at 37 oC for 30 min. The reaction was stopped by the 
addition of the malachite green solution and 34% aqueous sodium citrate, and the absorbance at 
650 nm was determined in a 96-well microtiter plate reader. In the microtubule-stimulated 
dynein motor domain ATPase kinetic study assay, paclitaxel (20 µM final concentration) was 
added to bovine tubulin. The mixture was incubated at 37ºC for 2 h to allow formation of 
microtubules, which were collected by centrifugation at 20,000 rpm in a Jouan MR23i 
microcentrifuge at 4ºC for 30 min. The pellet was then resuspended in the exchange buffer and 
adjusted to the desired final concentration. 
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2.2.17 Hsp70 and Hsp90 ATPase assays 
Recombinant human Hsp70 was from Assay Designs, Inc. The yeast homolog of Hsp90, 
Hsc90 (Hsc82p), was isolated as described previously72 from Saccharomyces cerevisiae yeast 
strain ECUpep4 with deletions in the chromosomal HSC82 and HSP82 genes and that encodes 
HSC82 on a 2 µm plasmid. The effects of the compounds on steady-state Hsp70/Hsp90 ATPase 
activity were measured as follows.  Test agent (100µM final concentration) or vehicle (DMSO) 
were preincubated with Hsp70/Hsp90 (3µg of Hsp70 or 6.25µg of Hsp90) on ice for 15 min.  
ATP hydrolysis was assayed at 30oC in ATPase reaction buffer (50mM Hepes, pH 7.4, 
containing 50mM NaCl, 2mM MgCl2 and 10mM dithiothreitol) with 0.05mM ATP and 0.2µCi 
[32P]ATP (3000 Ci/mmol; PerkinElmer, Inc.) in a final volume of 20 µL. At the specified time 
points, 2 µL aliquots were removed and added to 4 µL of stop solution (2 M LiCl, 4 M formic 
acid, 36 µM ATP) on ice to quench ATP hydrolysis. Aliquots of each reaction time point were 
spotted onto cellulose PEI thin layer chromatography plates (Selecto Scientific Inc.), which were 
developed with 0.5 M LiCl/1M formic acid solution and imaged with a PhosphorImager system 
(FUJIFILM Inc.) to determine the percentage of ATP hydrolyzed to ADP+Pi.  MAL3-10167 was 
used as the positive control in the Hsp70 assay and novobiocin73 was used as the positive control 
in the Hsp90 ATPase assay. 
2.2.18 Myosin Ca2+-ATPase assay 
The malachite green assay was used to determine the ability of the compounds to affect 
the Ca2+-stimulated myosin ATPase activity. Rabbit skeletal muscle myosin II (Cytoskeleton Inc., 
(25 µg/mL final concentration) and the test agents (100µM final concentration), as well as the 
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positive control (purealin42, a known myosin Ca2+-ATPase inhibitor, 20µM final concentration) 
and the negative control (DMSO only), were premixed in the reaction buffer (50 mM Tris-HCl, 
pH 7.9, containing 0.23 M KCl and 2.5 mM CaCl2).  ATP (2.5 mM final concentration) was 
added to initiate the reaction. The reaction mixture was incubated at room temperature for 30 
min. The malachite green assay was then performed as described above. 
2.2.19 Cellular levels of soluble and polymerized tubulin 
Soluble and polymerized tubulin levels in cells were determined with a Western blot 
procedure described previously74, 75. Briefly, cells were plated in 6-well plates and allowed to 
attach for 48 h, then treated with the indicated concentrations of the compounds. After 8 h, cells 
were detached by trypsinization, washed with HBSS, then lysed in 0.1M 2-(morpholin-4-
yl)ethanesulfonic acid (Mes), pH 6.75, containing 0.1% Triton X-100, 1 mM MgSO4, 2 mM 
EGTA and 4 M glycerol. The lysate was centrifuged at 14,000 rpm in an Eppendorf 
microcentrifuge. The supernatant (soluble tubulin fraction) and pellet (polymerized tubulin 
fraction) were dissolved in the in the cell lysis buffer. Protein samples were boiled in loading 
buffer, loaded onto 10% polyacrylamide gels, and separated by electrophoresis. Proteins were 
transferred to polyvinyldifluoride membranes (Biorad), using a Biorad Transblot Semidry system. 
After washing, blocking, and treating with appropriate antibodies, protein bands were detected 
using the Amersham ECL Western blotting system and Fuji film. Densitometric analyses were 
performed with ImageJ (v. 1.32j) software. 
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2.2.20 Tubulin polymerization assay 
Tubulin assembly was monitored turbidimetrically at 350 nm in temperature controlled, 
multichannel Beckman DU4700 spectrophotometers as described previously5. Reaction mixtures 
without test compounds contained tubulin (10 µM, 1.0 mg/mL) in 1M monosodium glutamate, 
pH 6.9, containing GTP (400 µM if present). Baselines were established after addition of all 
reaction components except the test compounds to the cuvettes held at 0°C. Compounds 
predissolved in DMSO (1% final concentration) were added to give the indicated final 
concentrations, and the reaction mixtures (0.25 mL final volume) were subjected to the indicated 
sequential temperature changes. 
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3.0  BIOLOGICAL EVALUATION OF A PUREALIN LIBRARY 
3.1 Introduction 
Antiproliferative assays are widely used to evaluate the activity of new agents against 
carcinoma cells and are a requisite part of the drug discovery process. The 21 purealin and 
purealidins were assessed for antiproliferative and potential cytotoxic activity against a panel of 
human carcinoma cells, as well as against a mouse leukemia cell line. Four well-established 
human carcinoma cell lines were examined: MDA-MB231 (breast epithelium; mutant TP53), 
PC-3 (prostate epithelium; TP53 null), 2008 (ovarian epithelium) and HT-29 (colon; TP53 null). 
These cell lines were chosen in part because they are readily available, they can be used as 
xenotransplants in immunocompromised mice for antitumor studies, these cancer types represent 
a large percentage of new cancers reported, the cell lines have similar growth characteristics, are 
particularly sensitive to antimitotic agents, and represent a majority of the solid tumors found in 
humans. The L1210 mouse leukemia cell line was chosen for this assay to compare data obtained 
here against that reported in the literature for purealidin A26. 
The MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium] assay was used here. It is a colorimetric method for determining the number of 
viable cells in proliferation or cytotoxicity assays.  In this assay, the MTS tetrazolium compound 
is reduced by cells into a colored formazan product that is soluble in tissue culture medium76. 
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This conversion is presumably accomplished by the NADPH or NADH produced by 
dehydrogenase enzymes in metabolically active cells77. Assays are performed by adding a small 
amount of the MTS reagent directly to culture wells, incubating for 1 h and then recording 
absorbance at 490nm minus that observed at 630nm with a plate reader. The quantity of 
formazan product as measured by the amount of 490nm absorbance is directly proportional to the 
number of living cells in culture78. The absorbance found at 630nm was used to remove any 
background contributed by excess cell debris, fingerprints and other nonspecific absorbance. The 
MTS assay is a convenient and fast way to determine the cell numbers and thus the 
antiproliferative activity of the compounds. 
 
Figure 14. Flow diagram illustrating the preparation of brain cytoplasmic dynein. 
[From Paschal et al., Methods Enzymol, 1991. 196:181 ref. 79] 
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Cytoplasmic dynein was originally identified as MAP 1C and purified from calf brain by 
Prof. Vallee and colleagues13,79. Dynein produces forces along microtubules and hydrolyzes ATP 
to ADP and free phosphate. When microtubules are sedimented in the absence of ATP, most of 
the dynein will co-sediment. However, when microtubules are sedimented in the presence of 
ATP, only a trace amount of  the dynein will sediment79. This is the basis for the dynein 
preparation. Also, GTP will extract kinesin and dynamin from microtubules80,81, helping to 
eliminate these two proteins from the dynein preparation. A flow diagram illustrating the 
preparation of brain cytoplasmic dynein by Vallee’s method is shown in Figure 14. Once dynein 
has been released from microtubules, it can be purified from trace contaminating polypeptides by 
sucrose density gradient centrifugation (Figure 15). 
 
Figure 15. SDS-PAGE of bovine cytoplasmic dynein after sucrose gradient 
centrifugation.  
[From Paschal et al., Methods Enzymol, 1991. 196:181 ref. 79] 
Also, from the intermediate steps in the regular tubulin purification and isolation work in 
the Day lab, it should be possible to isolate cytoplasmic dynein, one of the MAPs, from tubulin 
preparations. Microtubules with MAPs were obtained following the regular steps in tubulin 
preparation. After additon of GTP to extract kinesin and dynamin from the microtubules, ATP 
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was added to release the dynein from the microtubules followed by sucrose density gradient 
centrifugation. 
The dynein heavy chain and its related components must be characterized after the 
separation work. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
used to determine the relative purity of dynein heavy chain. Matrix-assisted laser desorption 
ionization-time of flight/time of flight- mass spectrometry/mass spectrometry (MALDI-
TOF/TOF-MS/MS) was used to identify the cytoplasmic dynein heavy chain, any isotypes, and 
adapter proteins co-purified from bovine brain. The MS work is covered in chapter 3.3.2. 
Since dynein heavy chain is an ATPase that can hydrolyze ATP to ADP and free 
phosphate, the ATPase activity of the purified sample can be measured by the free phosphate it 
released. The malachite green assay is a convenient way to measure free phosphate. Inorganic 
phosphate (Pi) forms complexes with ammonium molybdate, and the malachite green acts as 
additional ligand and colorimetric indicator for this reaction. Any instability of the signal was 
overcome by the addition of sodium citrate after the malachite green reagent. The absorbance 
maximum of the Pi-containing complex can be measured at ~650 nm82. 
It is reported that the ATPase activity of dynein heavy chain can be activated by the 
presence of microtubules13, the ATPase activity of dynein heavy chain can be measutred as a 
function of microtubule concentration. The known dynein ATPase inhibitor EHNA was used as a 
positive control in the ATPase assay, as well as an indicator of the success of the purification 
work41. 
Western blotting is an immunochemical technique commonly used to positively identify 
the presence of a specific protein in a complex mixture and to obtain qualitative and 
semiqualitative data about the level of the protein. After electrophoresis, the separated proteins 
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are transferred onto a polyvinylidene fluoride (PVDF) or nitrocellulose membrane. The 
transferred proteins are exposed to a primary antibody for the protein, weak and nonspecific 
complexes are broken by washing steps, and the presence of highly retained antibody (i.e., 
specific binding) is detected by a variety of means. Here, an enzyme-labeled antibody was used 
as a probe. A substrate that reacts with that enzyme to form a chemiluminescent product is then 
added and resulting emitted light is quantified by either a chemiluminescence detector and/or by 
captured the light emitted through use of sensitive x-ray film. 
Mass spectrometry has developed into a powerful tool to analyze proteins for  
information such as the protein sequence, some  three dimentional structure information, as well 
as any post-translational modifications of the protein83-85.  With the matrix-assisted laser 
desorption ionization (MALDI) method, nonvolatile molecules can be readily introduced into the 
gas phase and analyzed by mass spectrometry. The MALDI sample consists of a solid mixture of 
analyte and a crystalline matrix on a sample plate that is excited by laser light, resulting in soft 
ionization. Ions are guided by optics into the mass-to-charge ratio segregator (i.e., the mass 
spectrometer) (Figure 16A). The matrix is an organic acid with a chromophore absorbing at the 
laser wavelength, such as α-cyano-4-hydroxycinnamic acid (Figure 16B). 
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Figure 16. Schematic of MALDI (A) and structure of the matrix molecule α-cyano-
4-hydroxycinnamic acid (B). 
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Typsin digestion has become a standard method in proteomic analysis. Trypsin 
hydrolyzes polypeptides on the carboxyl side of arginine and lysine residues. In-gel digestion of 
polyacrylamide gel electrophoresis (PAGE)-separated proteins has proved to be an efficient 
method to generate peptide fragment mixtures suitable for mass spectrometric analyses and 
comparison to theoretical peptides from in silico digests of the proteins coded by genes found in 
genomics databases. This process of matching experimentally measured peptide masses to the 
theoretical masses found by in silico manipulations of genomics databases is known as peptide 
mass fingerprinting. 
3.2 Antiproliferative activities of purealin library components 
The 21 purealidins and purealins were assessed for antiproliferative activity against a 
small panel of human carcinoma cells [MDA-MB231 (breast), PC-3 (prostate), 2008 (ovarian) 
and HT-29 (colon)] as well as against the mouse L1210 leukemia cell line. The L1210 cells were 
used to compare data obtained here against that reported in the literature for purealidin A19. The 
procedure is described in Chapter 2. In short, cells were plate in 96-well plate and allowed attach 
for 72 h. Cells were treated with compounds for another 72 h. The MTS assay was used to 
determine cell viability. The 50% growth inhibitory (GI50) values obtained (Table 1) showed 
purealin and purealidin A to be inactive against the human cell lines. However, some of the 
purealidin A analogues, for example, ortho/chlorophenyl/Cl-purealidin A and 
ortho/indolinyl/Cl-purealidin A, showed low micromolar antiproliferative activity. The mouse 
leukemia cells, on the other hand, were uniformly sensitive to the individual library components. 
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Table 1. Antiproliferative activities of the purealin/purealidin library. 
GI50 (µM) 
Compound 
2008 MDA-MB231 HT29 PC3 L1210 
para/phenyl/Br-purealidin A 29 ± 2 27 ± 0 31 ± 3 31 ± 3 6.4 ± 2.2
para/methoxyphenyl/Br-purealidin A 24 ± 3 17 ± 2 20 ± 5 21 ± 5 2.8 ± 2.8
para/chlorophenyl/Br-purealidin A 29 ± 1 27 ± 2 31 ± 1 30 ± 4 7.8 ± 2.5
para/indolinyl/Br-purealidin A 27 ± 1 24 ± 2 26 ± 4 26 ± 9 5.8 ± 1.2
para/phenyl/H-purealidin A 30 ± 5 >50 27 ± 4 31 ± 6 6.2 ± 0.9
para/methoxyphenyl/H-purealidin A 31 ± 12 48 ± 14 30 ± 9 39 ± 4 9.9 ± 6.1
para/chlorophenyl/H-purealidin A 27 ± 3 26 ± 1 27 ± 1 33 ± 4 6.5 ± 2.0
para/indolinyl/H-purealidin A 26 ± 2 25 ± 1 30 ± 1 32 ± 6 7.6 ± 1.9
ortho/phenyl/Br-purealidin A 19 ± 5 5.7 ± 0.8 5.3 ± 0.2 19 ± 6 6.3 ± 0.4
ortho/methoxyphenyl/Br-purealidin A 25 ± 2 8.8 ± 0.6 4.9 ± 0.6 35 ± 15 6.2 ± 0.9
ortho/chlorophenyl/Br-purealidin A 5.6 ± 0.9 5.6 ± 0.7 5.3 ± 0.2 15 ± 7 6.3 ± 0.8
ortho/indolinyl/Br-purealidin A 7.5 ± 0.4 6.7 ± 1.0 6.0 ± 0.1 31 ± 6 5.4 ± 0.9
ortho/phenyl/Cl-purealidin A 8.8 ± 2.7 7.6 ± 3.2 5.6 ± 0.2 31 ± 7 7.5 ± 0.9
ortho/methoxyphenyl/Cl-purealidin A 29 ± 1 24 ± 2 6.2 ± 1.7 32 ± 11 6.9 ± 0.5
ortho/chlorophenyl/Cl-purealidin A 5.4 ± 0.6 5.2 ± 0.9 5.5 ± 1.8 7.8 ± 0.9 5.9 ± 0.5
ortho/indolinyl/Cl-purealidin A 5.7 ± 0.1 5.3 ± 0.0 6.0 ± 0.6 5.0 ± 1.1 5.8 ± 1.1
Lipopurealin A 28 ± 3 28 ± 1 29 ± 2 30 ± 4 9.0 ± 1.9
Lipopurealin B 29 ± 1 28 ± 3 30 ± 0 25 ± 9 12 ± 4 
Lipopurealin C 5.7 ± 1.2 7.0 ± 0.4 20 ± 3 32 ± 3 9.7 ± 1.6
Purealidin A >50 >50 >50 >50 4.7 ± 1.6
Purealin >50 >50 >50 >50 3.2 + 1.2
Discodermolide (nM) 2.7 ± 1.7 40 ± 7 28 ± 9 52 ± 8 9.2 + 4.3
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3.3 Dynein isolation and purification 
3.3.1 Purification of bovine brain cytoplasmic dynein heavy chain 
In order to test if the purealin library has any effect on dynein heavy chain ATPase 
activity, bovine cytoplasmic dynein heavy chain was purified from fresh bovine brain following 
the procedure described in Chapter 2. The Coomassie blue-stained SDS-PAGE of sucrose 
density gradient fractions in the standard purification of dynein heavy chain is shown in Figure 
17A. It was similar to the standard SDS-PAGE of the sucrose gradient in Figure 15. The top 
bands are dynein heavy chain. Fractions 6 and 7 were well-seperated dynein-enriched fractions. 
The presence of dynein heavy chain was further verified by Wester blotting (Figure 17B). Using 
rabbit anti-dynein heavy chain polyclonal IgG, dynein heavy chain was found in fractions 6 and 
7, but was unlikely to in fraction 5 even though there was a strongly-staining protein at the top of 
the SDS-PAGE gel in that fraction. 
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B
 
Figure 17. Coomassie blue-stained SDS-PAGE (A) and anti-dynein heavy chain 
Western blot (B) analysis of sucrose density gradient fractions in the standard purification 
of dynein heavy chain.  
 
Figure 18. Anti-dynein intermediate chain Western blot analysis of sucrose density 
gradient fractions 3-8. 
 
The protein concentration in fractions 5-7 was tested with the Bio-Rad protein reagent 
(Figure 19A). The ATPase activity of different dynein fractions was estimated with the malchite 
green-based ATPase assay (Figure 19B). From the results, the ATPase activity of dynein fraction 
7 was found high, especially when the small amount of protein in the solution was taken into 
consideration. The ATPase activity of fraction 6 was reasonable, not much ATPase activity was 
observed in fraction 5. With this information in hand, fractions 6 and 7 were used for analysis of 
the potential cytoplasmic dynein heavy chain inhibitors. 
 46 
A Protein Concentration
0
10
20
30
40
50
60
70
5 6 7
Dynein Fraction #
[P
ro
te
in
] /
 u
g/
m
l
B
5
6
7
0.00
200.00
400.00
600.00
800.00
A
TP
as
e 
nm
ol
/m
in
/m
g
Fraction Number
Cytoplasmic Dynein ATPase activity
Figure 19. The protein concentration (A) and ATPase activity (B) of different 
dynein purification fractions 5-7. 
 
Since dynein ATPase activity is dependent on the concentration of microtubules, the 
relationship between the concentration of tubulin and purified cytoplasmic dynein ATPase 
activity was tested (Figure 20). The result showed that microtubules behaved as a specific 
activator of the ATPase activity of the purified dynein, indicating the success of the purification 
work. The inhibitory effects of EHNA on cytoplasmic dynein ATPase activity is shown in Figure 
21.  
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Figure 20. ATPase activity of brain cytoplasmic dynein as a function of microtubule 
concentration. 
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Figure 21. Inhibitory effect of EHNA on bovine cytoplasmic dynein ATPase activity. 
 
 
Figure 22. Coomassie blue-stained SDS-PAGE analysis of sucrose density gradient 
fractions in the glycerol-based dynein purification. 
 
An attempt was also made to purify dynein heavy chain during the standard protocol of 
tubulin isolation from bovine brain, since dynein is actually one of the MAPs. The procedure 
was descried under section in Chapter 2. The resulting SDS-PAGE analysis after the sucrose 
density gradient centrifugation and staining of the developed gel with Coomassie blue is shown 
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in Figure 22. Fractions 2-4 were enriched in dynein, but the lower molecular radius bands around 
50kDa were not as well separated as those in the standard dynein preparation (Figure 17). 
3.3.2 Characterization of bovine cytoplasmic dynein by mass spectrometry 
The intermediate prep during the glycerol-based dynein preparation procedure was 
segregated by SDS-PAGE stained with Coomassie blue (Figure 23). There were three major 
bands in the gel: one with an MR of ca. 500kDa and two around 50kDa. These bands were 
excised from the gel, digested in-gel with trypsin and the released peptides were analyzed by 
MALDI-TOF-MS and MALDI-TOF/TOF-MS/MS. 
 
Figure 23. Coomassie blue-stained SDS-PAGE gel used in the mass spectrometric 
analysis of dynein fractions 
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Figure 24. MALDI-TOF mass spectrum of spot 1 
Table 2. Peak assignments of mass spectrum of spot 1 
 
61/272 matches (22%).      
Acc. #: P34036 Species: DICDI Name: Dynein heavy chain, cytosolic (DYHC)
Index: 142453 MW: 538824 Da pI: 6.2     
m/z MH+ Delta Missed Database 
Submitted Matched Ppm 
Modifications 
Cleavages Sequence 
1005.579 1005.5403 39 1Met-ox 1 (R)KMINDLQK(M) 
1009.52 1009.5318 -11  1 (R) SDLREYVK (A)
1019.515 1019.5314 -16  0 (K) NPYYPIPR (Y)
1037.559 1037.509 49 pyroGlu 1 (R)QLDTYMKR(V) 
1061.594 1061.5843 8.7  1 (R) KSLEDTLQK (L)
1063.538 1063.5536 -15  0 (R) SATSPALFNR (C)
1076.547 1076.5376 8.6  0 (K) LSSWEADLR (Y)
1137.65 1137.6268 20  0 (R) TILGSTIYGGR (I)
1178.593 1178.5404 45 1Met-ox 0 (K)TSFLDSSFMK(N) 
1188.613 1188.6523 -33  1 (R) LATAKNAMNVR (V)
1201.636 1201.6078 23 pyroGlu 1 (R)QGRQNYVTPR(H) 
1214.629 1214.6606 -26  1 (R) TGQDLLQRQR (F)
1302.722 1302.6905 24  1 (K) ENSKEVELLGGK (N)
1302.722 1302.7018 15  1 (K) ILQESKSINDR (I)
1332.673 1332.6946 -16  1 (K) EMKQSIGAVNQK (I)
1332.673 1332.7276 -41  1 (R) TTQNIKDPLFR (C)
1441.715 1441.7579 -30  0 (K) VTPEFSTLVASYK (R)
1441.715 1441.7763 -43  1 (K) DARELQVQLDVR (N)
1446.874 1446.8936 -14  0 (K) LTFALQLTIISVK (G)
1554.807 1554.7474 38  1 (K) SSDFDDDLRMLLK (R)
1579.992 1579.9423 31  0 (K) VSGAPLILEVLAIER (I)
1611.856 1611.907 -32  1 (R) KNATISEAIPQLQAK (I)
1658.873 1658.8616 7.1 1Met-ox 0 (R)FVAWMNGLSIYTIK(V) 
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1759.96 1759.8979 35  1 (R) GATHEYESQLIERVK (E)
1775.874 1775.9631 -50  1 (K) WLICLRQQVPSFSK (L)
1791.902 1791.903 -0.8  1 (R) VEGEWSAFNEILNRK (N)
1939.001 1939.0475 -24 1Met-ox 0 (R)LFMTSEIHPALPANLLR(M) 
1958.078 1958.0751 1.3  0 (R) HYLDFINQVVLLINEK (R)
1958.942 1958.9751 -17  0 (R) FYFVGDEDLLEIIGNSK (D)
2027.136 2027.0523 41  1 (K) IMEPNFITSIINYDTKK (M)
2027.136 2027.0523 41  1 (K) KIMEPNFITSIINYDTK (K)
2120.11 2120.0732 17 1Met-ox 0 (R)ALLEAIQTMDGCTLEGLVR(L) 
2138.13 2138.0657 30  0 (K) TTSWEVYLEAIEQVDNIK (S)
2177.179 2177.078 46  1 (K) LVDHIQQNSSDWKQFFGK (D)
2185.127 2185.1617 -16  0 (R) DAVVSSLVYIHQTIGEANIR (L)
2185.127 2185.1844 -26  1 (K) SVLSRFVAWMNGLSIYTIK (V)
2201.135 2201.1793 -20 1Met-ox 1 (K)SVLSRFVAWMNGLSIYTIK(V) 
2223.125 2223.1985 -33  1 (R) IKPLREEVEQLENAANELK (L)
2232.148 2232.113 15  1 (R) YIPLGWTKFFEFNDADLR (G)
2238.18 2238.1328 21  1 (K) EVKSSSPLLLCSVPGYDASSK (V)
2244.15 2244.1229 12  0 (K) WYSVPETISLSVWISDFSK (R)
2252.076 2252.1147 -17  1 (R) RNLHVVFTMNPASPDFHNR (S)
2268.222 2268.1096 50 1Met-ox 1 (R)RNLHVVFTMNPASPDFHNR(S) 
2278.18 2278.1607 8.4  1 (R) TYAQTSGKVTPEFSTLVASYK (R)
2298.323 2298.3033 8.7  1 (R) ILSAVSQQIQTIQVALKENSK (E)
2317.066 2317.0988 -14  1 (R) EAITKGYLEDPGFDYETVNR (A)
2351.104 2351.2043 -43  1 (K) IQFVGACNPPTDAGRVQLTHR (F)
2404.152 2404.2036 -21  1 (R) NGLILDSEEELYKYFTSQVR (R)
2428.266 2428.2652 0.19  1 (R) FYFVGDEDLLEIIGNSKDIIK (I)
2529.269 2529.3434 -29 1Met-ox 0 (K)ILQLHQILNINHGVMMVGPSGGGK(T) 
2546.284 2546.1947 35 1Met-ox 0 (R)YPLVIDPSGQAMEFLMNQYADK(K) 
2603.325 2603.3002 9.6 1Met-ox 1 (R)LLYSLMWGLGGSMGLVERENFSK(F) 
2619.37 2619.2951 29 2Met-ox 1 (R)LLYSLMWGLGGSMGLVERENFSK(F) 
2799.455 2799.4834 -10 pyroGlu 1 (R)QNYVTPRHYLDFINQVVLLINEK(R) 
2907.435 2907.3201 39  1 (K) DFDWLYHMRYYYDATQENVLHK (L)
2926.412 2926.5103 -33  1 (R) WVYLQGIFSGSGDINQLLPAESTRFK (S)
2947.434 2947.4123 7.5  1 (R) FNRYPLVIDPSGQAMEFLMNQYADK (K)
2983.455 2983.4114 14  0 (R) HWIIFDGDVDPEWVENLNSLLDDNK (L)
3004.526 3004.4483 26  1 (K) ALGSQLGRFVLVFCCDEGFDLQAMSR (I)
3117.533 3117.6108 -25  1 (R) TIKPDDLGDKASSPEFLNLLQAGTTTWAK (N)
3119.532 3119.4223 35 2Met-ox 0 (K)VEETETVMQEISEVSALYNPMALSCSR(V) 
3290.665 3290.6176 14  1 (K) MFAGLANLTLDDEKTTIIGMSSAEGETVTFK (K)
3344.7 3344.7248 -7.6 2Met-ox 1 (K)QEWVEKILQLHQILNINHGVMMVGPSGGGK(T) 
3399.807 3399.7104 29  1 (K) RNENAQLQQQQQTTITSPILTSPPTTSSSSR (S)
3410.682 3410.7735 -27  1 (R) LVPVEEEIQDLKAVWVELSNTWQEIDSLK (E)
3655.923 3655.8965 7.3  1 (K) IQEQLQSIEQTTQMILNNLADSVLQDLSAQKR (K)
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Figure 25. MALDI-TOF- mass spectrum of spot 2 
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Figure 26. MALDI-TOF mass spectrum of spot 3 
 
 
 52 
950 1563 2176 2789 3402 4015
Mass (m/z)
3.7E+4
0
10
20
30
40
50
60
70
80
90
100
%
 In
te
ns
ity
4700 Reflector Spec #1 MC[BP = 1636.9, 36722]
16
36
.8
68
5
12
45
.6
21
3
11
30
.6
27
8
16
97
.8
63
8
19
59
.0
21
9
12
58
.7
22
2
11
59
.6
55
3
28
14
.3
77
9
16
52
.8
61
6
15
74
.8
45
0
10
53
.6
41
2
17
07
.8
91
1
18
29
.9
22
1
28
11
.3
72
8
12
87
.7
52
0
26
21
.3
60
4
11
83
.5
48
3
14
01
.7
19
6
17
23
.8
91
1
24
09
.2
39
7
20
87
.1
15
0
16
48
.8
70
2
30
77
.4
59
5
10
39
.6
21
8
18
73
.9
69
0
13
55
.6
80
4
20
46
.0
70
3
21
40
.1
12
5
16
05
.8
70
8
10
97
.5
77
3
19
43
.0
19
8
12
29
.6
27
6
28
19
.3
76
5
26
37
.3
48
6
27
38
.3
76
5
25
59
.3
48
1
19
84
.0
45
8
12
90
.7
53
2
14
19
.6
95
6
14
75
.7
84
4
11
79
.6
24
6
17
89
.9
29
0
18
33
.9
35
8
31
21
.4
56
8
24
44
.2
16
8
23
96
.2
40
2
23
47
.0
51
3
26
86
.5
57
1
15
55
.7
74
2
23
00
.1
18
4
17
48
.8
75
0
28
73
.3
89
9
21
85
.1
15
5
99
6.
52
66
22
25
.1
55
5
30
19
.4
39
2
31
65
.4
77
3
33
67
.6
94
8
29
20
.4
05
5
32
50
.6
33
5
32
92
.4
79
5
34
43
.6
69
2
35
85
.7
22
9
37
67
.8
42
5
36
46
.7
45
6
39
39
.1
83
6
37
17
.2
70
5
 
Figure 27. MALDI-TOF mass spectrum of spot 4. 
Table 3. Protein identification results by MALDI-TOFMS. 
MOWSE # of (%) % Mean Data 
Score Masses Cov Err Tol Spot 
 Matched  ppm ppm 
Protein MW 
(Da)/pI Species Protein Name 
1 9.25E+12 61 (22) 20 2.91 54.5 538824/6.2 DICDI Dynein heavy chain, cytosolic (DYHC) 
 
2 5.08E+07 17 (5) 34 18.4 64.2 70872/5.4 MOUSE Heat shock cognate 71 kDa protein 
3 5.59E+14 29 (8) 62 27.6 12.5 50136/4.9 MOUSE Tubulin alpha-1 chain 
4 9.64E+14 40 (9) 66 16.4 31.7 50419/4.8 MOUSE Tubulin beta-3 
The mass spectra of spots 1-4 are shown in Figures 24-27. The ProteinProspector search 
engine from UCSF and SwissProt.2004.08.31 database were used for database searching. The 
protein identification results are shown in Table 3. From the results, the high molecular weight 
band in the SDS-PAGE matched well to Dictyostelium (slime mold) cytosolic dynein heavy 
chain. Since bovine cytosolic dynein heavy chain was not an entry in the database used, at the 
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moment, it can only be stated that the protein has a high probability of being bovine cytosolic 
cytosolic dynein heavy chain. 
Moreover, the proteins co-purified with dynein heavy chain were also identified. The 
mass spectrum of the protein in spot 2 suggested it to be a kind of heat shock protein. 
Considering the MW of the band 2 is around 70 kDa and the known connection between dynein 
heavy chain and Hsp/Hsc70s, it is reasonable that the protein in spot 2 is one of the Hsp/Hsc70 
family members. The mass spectra of proteins in spots 3 and 4 were consistent with alpha tubulin 
and beta tubulin, respectively. These results were the expected. The peak assignments of the 
mass spectra from spot 1 are listed in Table 2. 
3.3.3 Expression and purification of dynein motor domain 
In order to obtain more pure protein with higher enzymatic activity, a collaboration with 
Prof. Richard Vallee at Columbia University Medical Center, a pioneer of dynein research, was 
established. His group had very recetly expressed cytoplasmic dynein heavy chain motor domain 
via a baculovirus expression system and purified the protein. I repeated portions of the 
procedure, described in Chapter 2, in his lab, In short, the 380-kDa motor domain fragment was 
cloned from the coding region for Gly1286–Glu4644 of rat cytoplasmic dynein by insertion into 
the baculovirus expression vector pVL1393 (BD Biosciences) with a C-terminal in-frame 
hexahistidine tag. Hi5 cells were infected with virus for 40 h. The cells were washed and 
resuspended in PBS and the recombinant motor domain fragments were extracted from the cells 
by homogenization in lysis buffer supplemented with protease inhibitor and 1mM ATP. The 
cytosolic extract (CE) and cell pellet (CP) from the Hi5 cells were collected. The supernatant 
from the CE was applied to a Ni2+-NTA affinity column equilibrated in lysis buffer, and the flow 
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through (FT) was collected.  Unbound material removed by washing with 10 volumes of 
washing buffer and the elution (W) was colleted as well. The protein was eluted in 6 volumes of 
elution buffer and fractions 1~6 were collected. Protein concentrations of each fraction were 
determined by the Bradford method, using albumin as a standard. Protein samples (CE, CP, FT, 
W and fraction 1~6) were loaded onto a 3~8% Tris-acetate gel for electrophoresis analysis 
(Figure 28). From the SDS-PAGE analysis results, enrichment of the desired 380 kDa protein 
was evident in fractions 1 and 2. Therefore, fractions 1 and 2 were collected as purified 
cytoplasmic dynein heavy chain motor domain and flash frozen, with subsequent storage at –80 
ºC. The protein obtained from baculovirus system was purer than that purified from bovine brain. 
Moreover, the ATPase activity of the expressed dynein motor domain was higher. 
 
Figure 28. SDS-PAGE analysis of protein samples from the baculovirus/Hi5 cell 
cytoplasmic dynein heavy chain motor domain expression system. 
CE, cytosolic extract; CP, cell pellet; FT, flow through; W, unbond materials; 1-6, elution 
fractions. 
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3.4 Biochemical evaluation of purealin library component 
From the results of the antiproliferative assay discussed in section 3.2, it was apparent 
that some of the purealidin analogues had antiproliferative activity. Although purealin and 
purealidin A did not show antiproliferative activity in human carcinoma cell lines, the hope 
remained that they would bind to the proposed drug target, cytoplasmic dynein. Since the 
cytoplasmic dynein was isolated from bovine brain, its enzymaticic character was identified and 
the sequence was supported by mass spectrometry, the ATPase inhibition assay was then 
included as a characterization of the purealin library. 
Fang et al. initially identified the inhibitory properties of purealin on dynein's ATPase 
activity43 (Figure 29). The ATPase activity of 21S dynein was measured at 25 ºC. The sample 
was preincubated in the absence of purealin and ATP for 5 min, followed by the addition of 
purealin and further preincubation for 5 min. The reaction was started by the addition of 1mM 
ATP and stopped by adding one-third volume of cold 15% trichloroacetic acid. The amount of 
inorganic phosphate liberated at 0, 4, and 8 min after the addition of ATP was determined by the 
method of Martin and Doty86. The results of this experiment provided one basis for the 
hypothesis tested here, that purealins could inhibit cytoplasmic dynein. 
 
Figure 29. Inhibition by purealin of ATPase 
activity of axonemes and outer-arm-depleted 
axonemes.  
Outer-arm-depleted axonemes were prepared by 0.6 
M NaCl extraction of the axonemes as described in 
Materials and Methods. The ATPase activity of 
intact (open circles) and outer-arm-depleted (filled 
circles) axonemes was measured at 25 °C in the 
assay solution containing 1 mM ATP in the absence 
or presence of increasing concentrations of purealin. 
Effect of purealin on the ATPase activity of the 
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NaCl extract (filled triangles) was also measured as above and presented in this figure. [From 
Fang et al. Biochemistry 1997, 36, (50), 15561-7, Ref. 42] 
 
 
Figure 30. Inhibition of bovine brain dynein ATPase activity by purealin and 
purealidin A. 
 
The ATPase inhibitory activities of purealin and purealidin A against purified bovine 
cytoplasmic dynein heavy chain is shown in Figure 30. The fifty percent dynein heavy chain 
ATPase inhibitory concentrations of the purealin library were calculated and are listed in Table 
4. The results indicated that purealin and purealidin showed ATPase inhibitory activities against 
the target with the IC50s of 0.24 µM and 10.9 µM, respectively. Most of the chemicals in the 
library did not show substantial inhibition.  Nevertheless, the current library formed a basic 
platform for future work. 
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Table 4. Fifty percent dynein heavy chain ATPase inhibitory concentrations of the 
purealin library. 
Compound IC50 (µM) 
para/phenyl/Br-purealidin A >50 
para/methoxyphenyl/Br-purealidin A >50 
para/chlorophenyl/Br-purealidin A >50 
para/indolinyl/Br-purealidin A >50 
para/phenyl/H-purealidin A >50 
para/methoxyphenyl/H-purealidin A >50 
para/chlorophenyl/H-purealidin A 43 ± 36 
para/indolinyl/H-purealidin A >50 
ortho/phenyl/Br-purealidin A >50 
ortho/methoxyphenyl/Br-purealidin A >50 
ortho/chlorophenyl/Br-purealidin A >50 
ortho/indolinyl/Br-purealidin A >50 
ortho/phenyl/Cl-purealidin A >50 
ortho/methoxyphenyl/Cl-purealidin A >50 
ortho/chlorophenyl/Cl-purealidin A >50 
ortho/indolinyl/Cl-purealidin A >50 
Lipopurealin A >50 
Lipopurealin B >50 
Lipopurealin C >50 
Purealidin A 10.9 ± 5.9 
Purealin 0.24 ± 0.06 
 
The abilities of the library components to inhibit the MT-stimulated ATPase activity of 
recombinant dynein motor domain were also examined. First, the library components were 
screened against 50 µg/mL of rat cytoplasmic dynein motor domain in the presence of 5 mg/mL 
paclitaxel-induced tubulin polymer. Purealin and purealidin A gave IC50 values of 35µM and 
42µM, respectively. The following compounds showed some inhibitory actions, but their IC50 
values were > 50µM: para/chlorophenyl/H-purealidin A, para/indolinyl/H-purealidin A, 
para/chlorophenyl/Br-purealidin A, ortho/indolinyl/Br-purealidin A and ortho/indolinyl/Cl-
purealidin A. The relationship of the concentrations of the inhibitors and the ratio of the dynein 
ATPase activity in the presence of compounds and without compounds was determined first. 
Purealin and purealidin A showed concentration-dependent inhibitory effects (Figure 31). 
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Recombinant dynein heavy chain (5 µg/ml) and 1 mg/ml paclitaxel-induced MTs were used in 
this assay. The reaction was induced by addition of 2mM ATP. The concentration-dependent 
dynein ATPase inhibition effect of purealin is shown in Figure 32.   
 
 
Figure 31. Dynein motor domain ATPase inhibitory activities of purealin, 
purealidin A and para/chlorophenyl/H-purealidin A.  
 
 
Figure 32. Inhibition by purealin of dynein ATPase activity.  
 
To investigate the kinetics of dynein ATPase activity in the presence of different dynein 
inhibitors, 50 µM purealin, 50 µM purealidin A and 50 µM para/chlorophenyl/H-purealidin A 
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were added into the system with different concentration of the substrate, ATP, to determine the 
Michaelis-Menten parameters of dynein (Figure 33a). The calculated Vappmax, KappM and Ki 
values of dynein’s ATPase activity with different inhibitors are shown in Table 5. The results 
further indicates the inhibitory effects of purealin and its analogues on dynein motor domain. 
The inhibitory effects of the three most potent compounds was in the order purealin > purealidin 
A > para/chlorophenyl/H-purealidin A. A Hanes-Woolf curve was generated and its pattern 
(Figure 33b) indicated the inhibitory effects of the purealins to be uncompetitive in nature. 
 
 
 60 
 Figure 33. Michaelis-Menten curve (A) and Hanes-Woolf curve (B) of dynein in the 
presence of difference inhibitors: purealin, purealidin A and para/chlorophenyl/H-
purealidin A.  
The reaction was initiated with different concentrations of ATP in the presence of 12.5 µg/mL of 
recombinant dynein heavy chain and 1 mg/mL of paclitaxel-induced MTs. No inhibitor, filled 
circle; 50 µM para/chlorophenyl/H-purealidin A, open circle; 50 µM purealidin A, filled 
triangle; 50 µM purealin, open triagle. 
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Table 5. The Vappmax, KappM and Ki values of dynein ATPase with and without 
different inhibitors. 
Inhibitor Vappmax (nmol/min/mg) KappM (M) Ki (M) 
No Inhibitor 4.57×102 9.06×10-8 --- 
50 uM 
para/chlorophenyl/H-
purealidin A 
3.87×102 7.33×10-8 2.95×10-4
50 uM Purealidin A 3.78×102 7.01×10-8 2.61×10-4
50 uM Purealin 2.91×102 6.05×10-8 8.49×10-5
3.5 P53 nuclear translocation experiments 
The 53 kDa tumor suppressor protein p53 (aka TP53 in humans) is a transcription factor 
involved in cell-cycle regulation, the initiation of apoptotic cell death, and of DNA repair87. 
Previous results from others have indicated that cytoplasmic dynein is responsible for the 
transportation of both wild-type and mutant p53 from the cytoplasm to the nucleus23,30. For 
example, Galigniana et al. have shown that the overexpressed, temperature-sensitive, mutant 
mouse p53 in HT29-tsp53 cells undergoes dynein-dependent movement to the nucleus. p53 
movement was examined in HT29-tsp53 cells expressing myc-labeled dynamitin. Dynamitin is a 
50-kDa subunit of the dynein-associated dynactin complex, and its overexpression blocks dynein 
function by dissociating the motor from its cargoes88,89. In HT29-tsp53 cells overexpressing 
dynamitin (Figure 34A), there was very little movement of p53 compared with surrounding 
nontransfected cells, where p53 accumulated in the nucleus after the switch to the permissive 
temperature. 
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 Figure 34. Overexpression of dynamitin inhibits p53 movement to the nucleus.  
A, HT29-tsp53 cells were transfected with pCMVH50m plasmid encoding for myc-tagged 
dynamitin (Dyt). p53 nuclear translocation was triggered by shifting the temperature from 39 to 
32 °C. The cells were double-stained for p53 (red) and dynamitin (green). Arrows, transfected 
cells. Bar, 10 μm. B, rate of nuclear translocation of p53 (mean ± S.E., n = 3) in cells transfected 
with empty vector (○) or with dynamitin (●). *, p≤ 0.005, significant difference. Adapted from 
Galigniana MD, et al, J. Biol. Chem. 279, 21, 22483 (2004), ref. 30. 
 
Cell-based immunofluoresence assays are another powerful tool to evaluate dynein-
inhibiting compounds. The Day lab and its collaborators have developed a working cell-based 
assay system useful for the evaluation of various chemical libraries75. Nuclear morphology and 
chromatin density, microtubule architecture, p53 levels and their subcellular locale, etc., can be 
used to compare changes in cell structure and function induced by novel chemical agents. The 
system allows for simultaneous analysis of multiple parameters in populations of cells when 
treated with test agents. When an antibody to wild type p53 with a fluorescently-labeled 
secondary antibody is employed, the induction and nuclear translocation of the protein after 
minor DNA damage,  by e.g., low concentrations of the topoisomerase I inhibitor camptothecin, 
can be visualized and analyzed (Figure 35). 
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 Figure 35. Dynein-driven nuclear uptake of wild type p53 in A549 cells treated with 
camptothecin (data courtesy of Dr. Kenneth Giuliano). 
 
Using fluorescent protein biosensors, the inhibition of dynein-driven cargo transport 
when cells are treated with dynein-perturbing library components can be determined. The assay 
that determines the nuclear localization of wt p53 by dynein after slight DNA damage with a 
sub-lethal concentration of the DNA-damaging agent camptothecin, by use of fluorescent labels 
in human lung cancer cells was developed. A549 lung cancer cells were cultured in RPMI 1640 
medium plus 10% FBS. Log phase growing cells were plated on collagen-coated slides/plates 
and incubated for 48h at 37 °C in a humidified 5% CO2 atmosphere. The cells were incubated in 
the presence of compounds for 20h. At the end of the experiment, the solution was removed from 
the microplates and immediately replaced with a solution of HBSS containing 4% formaldehyde 
and 10 μg/mL Hoechst 33342 to fix the cells and fluorescently label their nuclei. After 
incubation at room temperature for 20 to 30 min, the solution was removed from each well and 
replaced with HBSS. At this point, microplates could be sealed and stored at 4 °C overnight. 
After removing the HBSS from each well, 0.5% (w/w) Triton X-100 was added and the plate 
incubated for 5 min at room temperature to detergent-extract a fraction of the soluble cellular 
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components, including soluble tubulin heterodimers. The wells were then washed with HBSS 
(100 μL/well) followed by the addition of a primary antibody solution containing mouse anti-α-
tubulin (1:1000) and sheep anti-p53 (1:500) in HBSS. After incubation at room temperature for 
1h, the microplate wells were washed with HBSS as above, followed by the addition of a 
secondary antibody solution containing Cy5-labeled donkey anti-sheep (1:500) and Cy3-labeled 
donkey anti-mouse (1:1000) antibodies diluted in HBSS. After a 1h incubation at room 
temperature, the microplate wells were washed as above and HBSS was added (100 μL/well) 
before sealing the microplates. Labeled microplates could be stored at 4 °C for up to 2 weeks 
before high-content analysis. 
A 
 
B 
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Figure 36. EHNA blocks p53 translocation into the nucleus after DNA damage. 
 
EHNA was the first compound tested in the p53 nuclear translocation assay. A549 cells 
were treated vehicle only (DMSO, Figure 36A), 5 μM camptothecin (Figure 36B), or 5 μM 
camptothecin with different concentration of EHNA (Figure 36C, D) for 24h. The cells were 
fixed and stained with fluorescent markers. The translocation score was obtained as described in 
the following way: a score of 4 was given for nuclear fluorescence much greater than 
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cytoplasmic fluorescence, 3 for nuclear fluorescence greater than cytoplasmic fluorescence, 2 for 
nuclear fluorescence equal to cytoplasmic fluorescence, 1 for nuclear fluorescence less than 
cytoplasmic fluorescence, and 0 for nuclear fluorescence much less than cytoplasmic 
fluorescence. The translocation scores reported represent the means ± S.E. from three different 
areas in an experiment, in which ≥ 30 cells/area were counted. Without camptothecin, the p53 
distributed evenly in cytoplasm and nucleus to give a translocation score of around 2. However, 
after treatment with 5µM camptothecin for 24 h, most of the p53 entered into the nucleus. A 
lower concentration (0.5mM) of EHNA has very little inhibitory effect on the p53 nuclear 
translocation. However, with the treatment of 2.5mM EHNA, p53 failed to enter into the nucleus 
after DNA damage by camptothecin. This result further supports the hypothesis that chemical 
inhibition of dynein’s ATPase activity will also block the transportation of its cargo into the 
nucleus. 
The activity of purealin and its analogues were examined in the p53 nuclear translocation 
assay (Figure 37). Purealin at 50 µM showed weak inhibition of p53 nuclear translocation after 
DNA damage. One of the purealin analogues, para/chlorophenyl/H-purealidin A, also showed an 
inhibitory effect, but at a lower concentration of 5 μM. Purealin and para/chlorophenyl/H-
purealidin A both showed inhibitory effects against dynein motor domain ATPase activity in 
vitro (Chapter 3.4). However, purealin was not antiproliferative in human cancer cells, whereas 
para/chlorophenyl/H-purealidin A gave GI50 values in the low micromolar range (Chapter 3.2). 
One of the explanations for the lack of agreement between the cell-based and in vitro activity of 
the compounds is that they may be hitting cellular targets other than dynein. However, about a 
simpler explanation is that the cell-permeability of purealin, based on its action in vitro and in 
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cell-based antiproliferative as well as p53 nuclear translocation assays, simply does not enter 
cells as well as para/chlorophenyl/H-purealidin A. 
 
A 
 
B 
C 
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Figure 37. Inhibitory activity of purealin and para/chlorophenyl/H-purealidin A on p53 
translocation into the nucleus after DNA damage 
 
A high-throughout and high-content screening (HTS and HCS) system was further 
developed to study the p53 nuclear accumulation upon treatment of dynein inhibitors. HCS 
defines the effects that test agents have on the temporal and spatial regulation of multiple cell 
functions, and has been adopted by the pharmaceutical industry as a standard platform for 
compound screening 75. The procedure used here is described in Chapter 2. Briefly, A549 cells 
were plated on collagen-coated 384-well microtiter plates, allowed to attach, and then treated for 
24 h with DMSO or test agents. After the treatment period, the cells were fixed with formalin 
and their chromatin stained with Hoechst 33342. Cells were permeabilized and treated with 
primary antibodies for α-tubulin with fluorophore-labeled secondary antibodies. The three 
fluorescent channels were then examined on an ArrayScan II®, an automated fluorescence 
microscope system, after scanning the plates using either target activation or compartmental 
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analysis bioapplications, which give quantitative pixel distribution and density information in 
each channel on a per cell basis. An Omega XF93 filter set at excitation/emission wavelengths of 
350/461 nm (Hoechst), 494/519 nm (Cy5), and 556/573 nm (Cy3) was used for scanning and 
1000 cells/well were imaged at these wavelengths. The bioapplications portion of the software 
was used to perform automated image acquisition, characterization and classification of the cell 
population according to response relative to controls. 
A B
 
Figure 38. Representative composite immunofluorescent images from p53 nuclear 
translocation high content screening experiments.  
A, DMSO (1%). B, Camptothecin (2 µM). Each image represents tubulin polymer (Cy5, green),  
nuclear chromatin (Hoechst 33342: blue), and p53 (Cy3: red) fluorescence. 
 
Representative immunofluorescent images from ArrayScan depicting tubulin polymer 
(Cy5: green), nuclear chromatin (Hoechst 33342: blue), and p53 (Cy3: red) intensities are shown 
in Figure 38A-B. Upon the treatment of A549 cells with 2μM camptothecin, most of p53 
accumulated in the nucleus, as the image obtained (Figure 38B) showed clearly the expected 
phenotype, accumulation of red fluorescence in the nucleus. 
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Figure 39. Average florescent intensity in A549 cells after treatment with camptothecin 
(CPT). 
Red bars, the average florescent intensity of Cy5-labled p53 in nucleus; Blue bars, the average 
florescent intensity of Cy-3 labled tubulin in cells.  
 
The concentration of camptothecin needed to trigger nuclear translocation was first 
optimized using the ArrayScan system.  Different concentrations of camptothecin were added to 
A549 cells for 24 h and cells were fixed and fluorescently labeled. The ArrayScan was utilized to 
scan the plate and quantify the p53 nuclear translocation. In this case, the average nuclear Cy5 
intensity represents the extent of p53 nuclear accumulation (Figure 39). The results clearly 
showed that with increasing concentration of camptothecin, more p53 accumulated in the 
nucleus. 
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Figure 40. Average florescent intensity in A549 cell upon the treatment of EHNA. 
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Red bars, the average florescent intensity of Cy5-labled p53 in nucleus; Blue bars, the average 
florescent intensity of Cy-3 labled tubulin in cells.  
 
EHNA was included in the next experiments to investigate its inhibitory effects on p53 
nuclear translocation. Different concentrations of EHNA (starting from 5mM) were added to 
A549 cells for 24 h (Figure 40). There was a slight decrease of p53 nuclear intensity when the 
concentration of EHNA was present in the range of 9.77μM to 1.25mM. However, the p53 
nuclear intensities were significantly higher when the EHNA concentrations were 2.5mM and 
5mM. Part of the reason for this is the toxicity of EHNA. At the higher concentrations of EHNA, 
most of cells rounded up and went into apoptosis, which could cause the increase of nuclear 
fluorescence intensity. This is supported in part by the very lower number of cells that ArrayScan 
captured for analysis in these cases (i.e., the cell number decreased). 
0
50
100
150
200
0 0.9766 1.9531 3.9063 7.8125 15.625 31.25 62.5 125 250 500
[Purealin] / μM
Av
g 
nu
cl
ea
r C
y5
 in
te
ns
ity
cy5-p53
cy3-tubulin
 
Figure 41. Average florescent intensity in A549 cells after treatment with purealin. 
Red bars, the average florescent intensity of Cy5-labled p53 in nucleus; Blue bars, the average 
florescent intensity of Cy-3 labled tubulin in cells.  
 
Finally, the effect of purealin on camptothecin-induced p53 nuclear translocation was 
studied. Different concentrations of purealin (from 0.98μM to 500μM) along with 2μM 
camptothecin were added to A549 cells before fixing and immunostaining (Figure 41). Purealin 
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showed a weak concentration-dependent inhibitory effect on camptothecin-stimulated p53 
nuclear translocation. This ArrayScan-determined result obtained was consistent with the 
previous one in which the manual immunostaining and human-based fluorescence scoring was 
used (Figure 37). 
3.6 siRNA-based knockdown of dynein heavy chain 
RNA interference (RNAi) is the process of using specific sequences of double stranded 
RNA (dsRNA) to knock down the expression levels of complementary genes. RNAi technology 
has become a modern tool for the cell biological study of specific protein functions. The RNAi 
pioneers, Andrew Z. Fire and Craig C. Mello, were awarded the Nobel Prize in Physiology or 
Medicine in 2006 “for their discovery of RNA interference - gene silencing by double-stranded 
RNA”90. Here the intention was to use dynein heavy chain siRNA to knock down dynein heavy 
chain levels, which could potentially serve as a positive control in the evaluation of dynein 
inhibitors. 
 
Table 6. Dynein heavy chain siRNA sequences. 
 Sense (5’->3’) Antisense (5’->3’) 
siRNA 1 CGUACUCCCGUGAUUGAUGtt CAUCAAUCACGGGAGUACGtt 
siRNA 2 GCAAAAUAUUGAAAUUCCGtt CGGAAUUUCAAUAUUUUGCtg 
siRNA 3 GCCAAAAGUUACAGACUUUtt AAAGUCUGUAACUUUUGGCtt 
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Dynein heavy chain siRNAs 1, 2, 3 were obtained from Ambion, Inc (Table 6). A 
negative control siRNA was also obtained, which was a 19 base pair (bp) scrambled sequence 
with 3’ dT overhangs and a sequence with no significant homology to any known gene 
sequences from mouse, rat or human. The transfection procedure used is described in Chapter 2. 
In short, A549 lung cancer cells were plated in RPMI 1640 medium without antibiotics in 6-well 
plates. Oligonucleotide-OligofectamineTM complex in Opti-MEM I reduced serum medium were 
prepared according to the manufacturer’s instructions. The complex was added to cells and 
incubated at 37 ºC for 4 h. Opti-MEM medium with three times the normal concentration of 
serum and without antibiotics was added, and the cells were incubated for 48 h. Cells were then 
detached with trypsin, pelleted by centrifugation and resuspended in a lysing buffer. Cell extracts 
were separated by 6.5% SDS-PAGE in Tris-glycine-SDS buffer for 8 h. Western blotting 
analysis was performed with rabbit anti-dynein heavy chain antibody and mouse anti-dynein 
intermediate chain antibody. Band intensities were measured with ImageJ software. 
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Figure 42. siRNA knockdown of dynein heavy chain. 
 
A final concentration of 50nM negative siRNA or siRNAs 1, 2 or 3, as well as the 1:1:1 
mixture of siRNA 1, 2 and 3 giving a sum of 50nM, were transfected into A549 cells for 48 h. 
The results showed that 50nM of the individual siRNAs 1, 2, 3, as well as the mixture of the 
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three inhibited the dynein heavy chain expression level by 15%, 10%, 38% and 45%, 
respectively (Figure 42). It seemed that 50nM siRNA with 48 h of transfection time was not 
enough to totally knock down the dynein heavy chain level. Therefore, higher amounts of siRNA 
with longer transfection times were tried. siRNA 1 (150nM), 100nM and 150nM siRNA 2, and 
100nM and 150nM siRNA 3 were examined with a transfection time of 72 h. The results 
illustrated that these concentrations of siRNAs after the prolonged time of exposure dramatically 
knocked down the level of dynein intermediate chain. siRNA 2 at 150nM generated an 82% 
decrease of the level of dynein heavy chain (Figure 42). Thus, siRNA 2 was used at 150nM for 
72 h as a potential positive control in the cell-based p53 nuclear translocation assay.  
 Nuclei p53 Dynein 
Sc
am
bl
ed
 si
R
N
A
 
D
yH
C
 si
R
N
A
 
Figure 43. Immunostaining of nuclei, p53 and dynein heavy chain in A549 cells uppn 
treatment of scrambled siRNA or DyHC siRNA. 
A549 cells were transfected with a final concentration of 150nM scrambled siRNA or 150nM 
DyHC siRNA 2 for 72 hrs. Rabbit DyHC antibody and Alexa 555 anti-rabbit antibody were used 
for immonustaining of dynein heavy chain. Mouse p53 and Alexa 488 anti-mouse antibody were 
used for immonustaining of p53. 
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However, it seems that siRNA did not knock down the dynein activity in cells (Figure 
43). Therefore, it seems likely that the lifetime of cytoplasmic dynein in cells is too long for the 
siRNA approach to be useful in a screening protocol. 
3.7 Discussion 
Dynein plays an important role in variety of cellular processes. Recent work is beginning 
to uncover the mechanism of dynein movement and its power stroke22, 71, 91. A variety of 
molecules involved in cell growth control, including p53, Bim, cdc2 kinase, HDAC6, Hsp70 and 
Hsp90 have also been reported to interact with or be under control of cytoplasmic dynein23, 24, 29, 
30, 92. Motor activity and motor-cargo interactions in dynein and other motor proteins, such as 
kinesin and myosin, might represent attractive drug targets and are certainly of interest in the 
development of chemical biology tools. Recently, RNA interference technology has been applied 
against dynein as well as its regulatory polypeptides16, 93-96, showing that lowering the level of 
the cytoplasmic dynein heavy chain (and therefore its activity in bulk) leads to a block in 
mitosis16.  Effective small molecule dynein inhibitors could therefore be useful for further 
investigation of the cellular function of dynein in vivo.  
Very little is known, however, about the structural requirements needed for small 
molecules to inhibit dynein.  Agents that competitively inhibit the binding of ATP to the protein 
are the most studied, and redox active agents will also inhibit the protein. Neither of these seems 
appropriate for finding a selective agent, as ATP and redox balance are cell-wide requirements. 
The only non-ATP, non-inorganic and non-redox active agent known to inhibit the axonemal 
isoform of cytoplasmic dynein is the natural product purealin, which acted as the seminal lead in 
these studies. The results showed that synthetic purealin and two of its analogues inhibit MT-
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stimulated cytosolic dynein heavy chain's ability to hydrolyze ATP. Thus, the purealins might be 
useful for further physiological investigation of dynein function.  
Kon and coworkers97 showed that ATP binding and its hydrolysis only at the P1 site of 
dynein heavy chain are essential for the motor activities of cytoplasmic dynein, and suggested 
that the motor activities are also regulated by the other nucleotide-binding/hydrolysis sites.  For 
example, nucleotide binding at the P3 site is also critical for MT-activated ATPase and motility 
activities of cytoplasmic dynein.  It is known that purealin inhibits the ATPase activity of 
axonemal dynein but does not compete for the ATP binding site, whereas little is known about 
the kinetic properties of cytoplasmic dynein inhibitors. The kinetics of inhibitors in the 
cytoplasmic dynein motor domain ATPase assay were examined here. Plotting of the data in the 
Hanes-Woolf format showed no significant change in the y-intercept, which represents the value 
of Km/Vmax, in the presence of purealin, purealidin A and para/chlorophenyl/H-purealidin A. 
This indicates that the binding pattern of the purealins is uncompetitive,  meaning the inhibitors 
bind to a site that becomes available only after the ATP has bound to the P1 site, giving rise to 
the conclusion that purealins do not compete for the binding of ATP nor with its hydrolysis at the 
P1 site. The binding site of purealins is still unknown. 
Although purealin and purealidin A were inactive as human cancer cell antiproliferative 
agents, their inhibition of cytoplasmic dynein ATPase activity supports the hypothesis that 
purealin/purealidin and analogs are good leads for finding small molecules to inhibit this target. 
para/chlorophenyl/H-purealidin A showed reasonable antiproliferative activity against human 
carcinoma cell lines as well as against a mouse leukemia cell line, and inhibited dynein motor 
domain ATPase activity, providing correlative support of the hypothesis that small molecule 
inhibitors of the molecular motor can have antiproliferative effects. Compared to the effects on 
human cancer cell lines, the growth of the mouse leukemia L1210 cell line was uniformly 
sensitive to low micromolar concentrations of the purealin/purealidin library components. Since 
purealin has very weak inhibitory effects against p53 nuclear translocation assay and failed the 
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antiproliferation assay, there remained a need to search for more potent, cell-permeable and 
dynein-specific inhibitors. 
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4.0  DISCOVERY OF NEW SMALL-MOLECULE INHIBITORS OF CYTOPLASMIC 
DYNEIN BY A PHENOTYPIC SCREEN 
4.1 Introduction 
In Chapter 3, the biological evaluation of the cytoplasmic dynein ATPase inhibitor 
purealin and its analogues was given in detail. Although purealin and some of its analogues 
showed inhibitory effects against the ATPase activity of both bovine cytoplasmic dynein heavy 
chain and recombinant rat cytoplasmic dynein heavy chain motor domain, purealin showed only 
weak effect in cellular assays. Therefore, the search for new dynein inhibitors shifted to a 
chemical biology approach. Since it is known that the overexpression of dynamitin inhibits 
ligand-dependent movement of the glucocorticoid receptor (GR) to the nucleus, chemical 
inhibition of dynein movement will also lead to inhibition of GR translocation into the nucleus. 
Therefore, a phenotypic cell-based assay was established to screen compounds that block the 
hormone-stimulated GR nuclear uptake as putative dynein inhibitors. 
4.2 Chemical Libraries for screening 
A small (110-member) but structurally rich library synthetic library of compounds was 
obtained from University of Pittsburgh Center for Methodologies and Library Development 
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(UPCMLD). The compounds were chosen as a representative of a larger library with 
considerable scaffold and physicochemical property variability. The library members included 
tricyclic pyrroles, cyclopropyl(phenyl)alkylamides, cyclopentapyridines, 
quinolines/naphthoquinones, pyrimidinones and dihydropyrroles whose syntheses have been 
reported before27, 67, 98-101 (Figure 44). 
 
Figure 44. Structural classes within the UPCMLD initial discovery library. 
4.3 GFP-GR nuclear translocation screening results 
4.3.1 Inhibitory effect of EHNA on GFP-GR nuclear translocation 
In the GFP-GR nuclear translocation assay, a mouse mammary adenocarcinoma cell line 
(3617.4) stably expressing GFP-rat GR69 was used to illustrate the inhibition of nuclear 
translocation by dynein inhibitors. Treatment with a high concentration of EHNA blocked GFP-
GR nunclear translocation (Figure 3). GFP-GR expression in this cell line is under control of the 
“Tet-Off” inducible system. Cells were grown in DMEM supplemented with 10% FBS and 10 
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μg/mL tetracycline. Cells were routinely maintained in an incubator at 37 ºC, 5% CO2. At the 
time of transfer to test slides or 96-well plates, the medium was replaced with DMEM with 10% 
FCS without tetracycline to induce GFP-GR. Cells were then treated with test agents for 24 h. 
Receptor translocation was induced by adding 1μM dexamethasone (vehicle was ethanol) for 15 
min. The medium  
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Figure 45. EHNA blocks GFP-GR nuclear translocation.  
(A) Mouse mammary adenocarcinoma cells (3617.4) stably expressing GFP-rat GR were 
incubated with vehicle (DMSO) or drugs for 24 h. Cells were then treated for 15 min in the 
absence (-Dex) of presence (+Dex) of dexamethasone. (B) The bar graph presents the nuclear 
translocation scores in each condition. 
 
was then removed and cells were washed three times with phosphate buffered saline (PBS). Cells 
were fixed and permeabilized by immersion in cold methanol (–20 ºC) for 20 min. Mouse anti-α-
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tubulin (NeoMarkers), Cy3 donkey anti-mouse (Jackson ImmunoResearch) and Hoechst 33342 
were then used to fluorescently label microtubules and the nucleus. Cells were photographed 
with a Leica DC300F fluorescent microscope and scored for GFP-GR translocation as described 
above. After treatment with 2.5mM EHNA for 24h, hormone-stimulated GFP-GR nuclear 
translocation was significantly blocked (Figure 45). EHNA also showed a time-dependent 
inhibitory effect on the GFP-GR nuclear translocation (Figure 46). 
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Figure 46. Time-dependent inhibitory effect of 2.5mM EHNA against GFP-GR nuclear 
translocation.  
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(A) Mouse mammary adenocarcinoma cells (3617.4) stably expressing GFP-rat GR were 
incubated with vehicle (DMSO) or EHNA for 0, 4 or 8 h. Cells were then treated for 15 min in 
the absence (-Dex) of presence (+Dex) of dexamethasone. (B) The graph presents the nuclear 
translocation scores in each condition. 
 81 
4.3.2 Inhibition by purealin of GFP-GR nuclear translocation 
Purealin was also tested in the GFP-GR nuclear translocation assay. It showed a weak 
inhibitory effect against GFP-GR nuclear translocation (Figure 47). 
 
Figure 47. Purealin inhibition effect of  GFP-GR 
nuclear translocation.  
Mouse mammary adenocarcinoma cells (3617.4) 
stably expressing GFR-rat GR were incubated with 1% 
DMSO (A, B) , 100 μM purealin (C) or 10 μM 
geldanamycin (D) for 24 h. Cells were then treated for 
15 min in the absence (A) of presence (B-D) of 
dexamethasone. The bar graph (E) presents the nuclear 
translocation scores in each condition. 
 
4.3.3 Inhibitory effect of the UPCMLD library 
compounds on GFP-GR nuclear translocation 
A B 
 
C D 
 
The UPCMLD library described above was 
screened to identify any compounds that might block GFP-GR nuclear translocation. Cells were 
pretreated with library compounds or vehicle (DMSO) for 8 h or 24 h prior to dexamethasone 
(DEX) addition. After incubation with DEX, the cells were fixed and stained with Hoechst 
33342. Cells were then photographed with a Leica DC300F fluorescent microscope or an 
Olympus IX70 inverted microscope. Cells within images were then scored for GFP-GR nuclear 
translocation as described in Chapter 2. 
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Figure 48. GFP-GR nuclear translocation inhibitory effect of JUN266.  
(A) Example picture of Hoechst-stained nuclei and GFP-GR in 3617.4 cells upon the treatment 
of JUN266; (B) Translocation score of the negative control (-DEX), positive control (+DEX) as 
well as JUN266; (C) Chemical structure of JUN266 and its analogue, NEM. 
 
One of the compounds within the UPCMLD library, JUN266, showed an inhibitory effect 
against GFP-GR nuclear translocation (Figure 48). However, the structure of the compound 
provided some reasons to avoid pursuit of this hit. One is the toxicity of the compound. Upon the 
treatment of JUN266, it seemed that the cells failed to respond to hormone stimulation due to the  
fact that the cells seemed to have entered into JUN266-induced apoptosis, as could be seen from 
the morphology their nuclei presented (Figure 48A). Most of the nuclei shrank in response to 
JUN266. Another reason not to pursue this compound is the questionable specificity it might 
provide. JUN266 is a quinone and, like N-ethylmaleimide (NEM), is likely a sulfhydryl-reactive 
reagent. JUN266 could therefore block the GFP-GR nuclear translocation by some some non-
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specific redox reactions with, e.g., other ATPases or kinases. Therefore, JUN266 was not 
pursued in this context. 
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Figure 49. GFP-GR nuclear translocation inhibitory activity of the UPCMLD compounds.  
GFP-GR nuclear translocation inhibitory activity of library compounds CMC002042, 
PSI002042, PSI002043, PSI002049, STW001222 and STW001150. Mouse adenocarcinoma 
3617.4 cells expressing GFP-GR were pretreated with different compounds or vehicle (DMSO) 
and then incubated with dexamethasone (+DEX) or vehicle (ethanol, –DEX). 
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Figure 50. The nuclear translocation scores of the active UPCMLD compounds (left) and 
chemical structures of the compounds (right). 
 
Six of the library compounds inhibited dexamethasone-stimulated GFP-GR nuclear 
translocation (Figure 49) without perturbing cellular microtubule arrays. Results of quantitative 
analysis of the GFP-GR nuclear translocation and the chemical structures of the compounds that 
inhibited GFP-GR nuclear translocation are shown in Figures 50. EHNA was used as a positive 
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control and it blocked GFP-GR nuclear translocation when present at 2.5mM (Figure 45). 
Geldanamycin (GA), a known Hsp90 inhibitor, also served as a positive control (Figure 47D), 
giving results similiar with an earlier report102. 
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Figure 51. Representative images of GFP-GR nuclear translocation assay by IN Cell 
Analyzer 1000 system. 
3617.4 cells expressing GFP-GR (green, lower panel in each figure) and stained with Hoechst 
33342 (blue, upper panel in each figure). (A) –DEX (negative control); (B) +DEX (positive 
control); (C) 125μM purealin + DEX; (D) 4μM CMC002042 + DEX. 
 
A B 
 86 
C   
 
Figure 52. Quantification of GFP-GR nuclear translocation assay by IN Cell Analyzer 1000.  
(A) Concentration dependent inhibitory effect of 0.16, 0.8, 4, 20, 100μM CMC002042 (C7) on 
3617.4 GFP-GR nuclear translocation; (B) Concentration dependent inhibitory effect of 62.5, 
125, 250, 500 and 1000μM purealin (CMPD 1) on 3617.4 GFP-GR nuclear translocation; (C) 
Inhibitory effects of compounds PSI002042, PSI002043, PSI002049, STW001222 and 
STW001150. 
 
With the help of Drs. Dwayne W. Dexter and Ann del Campo at GE Healthcare Inc., the 
GFP-GR nuclear translocation assay results were further analyzed by the IN Cell Analyzer 1000 
system. A translocation index was automatically obtained for quantification of GFP-GR nuclear 
accumulation. Figure 51 shows representative images obtained from the IN Cell Analyzer 1000 
system. Compound CMC002042 showed a concentration-dependent inhibitory effect against 
DEX-stimulated GFP-GR nuclear translocation (Figure 52A). Purealin also showed a weak 
inhibitory effect against GFP-GR nuclear translocation in a concentration-dependent pattern 
(Figure 52B). The IN Cell Analyzer 1000 system also helped to further confirm earlier findings 
that compounds PSI002042, PSI002043, PSI002049, STW001222 and STW001150 inhibit 
hormone-stimulated GFP-GR nuclear translocation in 3617.4 cells (Figure 52C). 
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4.4 in vitro GR binding assay results 
The possibility that the compounds active as inhibitors of GFP-GR nuclear translocation 
were targeting GR directly needed to be ruled out. For example, hormone-dependent GFP-GR 
nuclear uptake would be prevented if hormone binding to GR was being inhibited. A GR 
competitor assay was therefore performed in which the compounds were tested for their ability to 
displace a glucocorticoid agonist from the ligand binding domain of the GR. Recombinant 
human GR was bound with fluorescently-labeled dexamethasone and then treated with test 
agents. After 2h, fluorescence polarization (FP) was measured. The fluorescent analogue of 
dexamethasone when bound to GR protein generates high FP values. The presence of a 
displacing ligand causes a decrease in the FP. Concentration-dependence curves were 
constructed. The one-site competition method in GraphPad Prism 4 software was used for 
constructing concentration–response curves and for calculating IC50’s. Dexamethasone gave an 
IC50 of 0.65 ± 0.01nM, while the test compounds had IC50 values above the highest concentration 
tested (200 μM). Thus, the compounds that blocked GFP-GR nuclear transport are unlikely to 
affect GR hormone binding (Figure 53). 
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 Figure 53. Low potency of the GFP-GR translocation-inhibitory compounds in an in 
vitro GR competition assay as compared to DEX (mean ± SD, N = 4).  
 
 
Figure 54. Low potency of the compounds in affecting hormone-specific GR binding 
as compared to DEX (mean ± SD, N = 2). 
 
Molecular chaperones play an important role in the nuclear translocation of GR. 
Specifically, a dynein-immunophilin-Hsp90-Hsp70-GR heterocomplex appears to be required 
for GR nuclear transport103. The GR competitor assay does not directly test the GR chaperone 
complex. If GR binds hormone, the chaperone complex is intact. Therefore, experiments were 
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performed to determine if the compounds altered the Hsp90-Hsp70-GR heterocomplex. For 
example, the known Hsp90 ATPase inhibitor geldanamycin (GA) blocks nuclear translocation of 
the GR by breaking the dynamic cycle of heterocomplex assembly/disassembly, which leads to 
Hsp90 degradation via the ubiquitin/proteasome pathway73. In order to corroborate the GR 
competitor assay, an in vitro hormone binding assay with [3H]dexamethasone was performed 
using cytosol isolated from untreated 3617.4 cells. A GR ligand in this assay will displace 
[3H]dexamethasone and decrease the specific binding. Dexamethasone gave an IC50 of 1.2 ± 
0.1nM, which is in the same range as found in the GR competitor assay. The GFP-GR 
translocation-inhibitory library compounds registered IC50 values greater than the highest 
concentration used (100μM) (Figure 54). This result further indicated that the compounds were 
neither GR ligands nor affected GR hormone binding. Furthermore, the results suggest that the 
compounds do not disrupt the GR heterocomplex containing various chaperones and co-
chaperones. 
4.5 Inhibition of dynein motor domain ATPase 
In order to ascertain if the compounds directly affected the desired target, a recombinant 
form of the full motor domain of rat cytoplasmic dynein heavy chain71 was used to test whether 
the compounds inhibit the protein's basal ATPase activity. The compounds that inhibited the 
GFP-GR nuclear translocation were first mixed with recombinant rat cytoplasmic dynein motor 
domain and the protein’s basal ATPase activity was assessed. Concentration-dependent 
experiments showed PSI002049 to have an IC50 value of 2.0±0.2μM. Four other compounds, 
PSI002043, STW001222, PSI002042 and CMC002042, had weaker concentration-dependent 
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inhibitory effects on the basal ATPase activity of dynein motor domain (Figure 55). 
 
Figure 55. Inhibitory activities of UMCMLD compounds against recombinant dynein 
heavy chain motor domain. 
The reaction was initiated by addition of 2 mM ATP in the presence of the indicated 
concentration of the compounds ( mean±SD, N=4). 
4.6 Kinetics study on the new dynein inhibitors 
The inhibitory ability of the new dynein inhibitors was further studied. First, different 
concentrations of cytoplasmic dynein motor domain were used to determine the concentration-
dependent inhibition by PSI002049 of phosphate release (Figure 56). To investigate the 
inhibitor’s effects on enzyme kinetics, different concentrations of PSI002049 (0, 2, 10, 50 μM) 
were each incubated with different concentrations of the substrate, ATP, to determine the 
Michaelis-Menten parameters of the dynein motor domain (Figure 57; calculated Vappmax, KappM 
and Ki values are given in Table 7). These results further show the inhibitory effects of 
compound PSI002049 on the dynein motor domain ATPase activity. An examination of the 
kinetics in the Hanes-Woolf format (Figure 57, right), wherein no significant change in the y-
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intercept was noted, indicated that the compound displayed uncompetitive inhibition, giving rise 
to the conclusion that the PSI002049 does not bind to the ATP site. The kinetics of inhibition by 
CMC002042, PSI002042, STW001222 and PSI002043 were also examined (Figure 58; Table 8) 
and revealed the uncompetitive inhibition of basal ATPase activity of the dynein motor domain. 
Finally, STW001222, PSI002043 and PSI002049 inhibited microtubule-stimulated dynein motor 
domain ATPase in an uncompetitive pattern (Figure 59; Table 9). 
 
Figure 56. Inhibition by PSI002049 of recombinant rat cytoplasmic dynein heavy chain 
motor domain-catalyzed release of free phosphate from ATP.   
Dynein motor domain was mixed with the test agent.  ATP (2 mM) was added to initiate the 
reaction and the concentration of free phosphate was determined after incubation at 37 C for 0.5 
h.  Each point is the mean of four determinations ± SD (some of the error bars are smaller than 
the symbols used). 
o
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Figure 57. Michaelis-Menten (left) and Hanes-Woolf (right) plots of basal dynein 
motor domain ATPase activity in the presence of different concentrations of PSI002049.   
The reaction was initiated with different concentrations of ATP in the presence of 21.25 µg/mL 
recombinant dynein heavy chain. 
 
 
Table 7. The Vappmax, KappM and Ki values of the ATPase activity of recombinant 
cytoplasmic dynein heavy chain motor domain in the presence of 2, 10 and 50 µM 
PSI002049. 
 
[PSI002049] (µM) Vappmax (s-1) KappM (µM) Ki (µM) 
0 2.52 150 
2 0.83 49 
10 0.13 32 
0.82 
50 0.04 29 
 
 
 
 93 
 Figure 58. Michaelis-Menten (left) and Hane-Woolf (right) plots of basal dynein 
motor domain ATPase activity in the presence of 50µM CMC002042, PSI002042, 
STW001222 and PSI002043.  
The reaction was initiated with different concentrations of ATP in the presence of 21.25 µg/mL 
recombinant dynein heavy chain. 
 
Table 8. The Vappmax, KappM and Ki values of the ATPase activity of recombinant 
cytoplasmic dynein heavy chain motor domain in the presence of 50µM CMC002042, 
PSI002042, STW001222 and PSI002043. 
Compound Vappmax (s-1) KappM (µM) Ki (µM) 
No inhibitor 2.60 145 --- 
CMC002042 1.53 80 62 
PSI002042 1.13 52 28 
STW001222 0.90 47 24 
PSI002043 0.90 45 23 
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 Figure 59. Michaelis-Menten (left) and Hane-Woolf (right) plots of microtubule-
stimulated dynein motor domain ATPase activity in the presence of 50µM STW001222, 
PSI002049 and PSI002049. 
The reaction was initiated with different concentrations of ATP in the presence of 12.75 µg/mL 
recombinant cytoplasmic dynein heavy chain and 1 mg/mL of paclitaxel-induced tubulin 
polymer. 
 
Table 9. The Vappmax, KappM and Ki values of the microtubule-stimulated ATPase 
activity of recombinant cytoplasmic dynein heavy chain motor domain in the presence of 
50µM STW001222, PSI002049 and PSI002049. 
Compound Vappmax (s-1) KappM (µM) Ki (µM) 
No inhibitor 5.16 157 --- 
STW001222 3.45 108 101 
PSI002043 2.88 93 63 
PSI002049 2.36 74 42 
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4.7 Specificity studies 
4.7.1 Hsp70 and Hsp90 ATPase assay results 
Compounds that inhibit GFP-GR nuclear translocation may do so by inhibiting the 
activities of receptor-associated chaperones, such as Hsp90 and/or Hsp70. Therefore, the effects 
of the compounds on the steady state ATPase activities of recombinant human Hsp70 and a close 
homologue of human Hsp90, yeast Hsc82p, were examined. Mixtures containing [32P]ATP and 
either Hsp70 or Hsc82p were incubated at 30 ºC in the presence of the compounds, established 
inhibitors (for Hsc82p, novobiocin73; for Hsp70, MAL3-10167) or vehicle (DMSO). The 
conversion of Hsp70/90-bound ATP to ADP•Pi was monitored by thin layer chromatography 
and phosphor image analysis. Whereas novobiocin and MAL3-101 inhibited the rate of ATP 
hydrolysis by their respective target chaperone proteins, none of the new dynein inhibitors at up 
to 100 μM had any significant inhibitory effect (Table 10, 11). 
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Table 10. Effects of the compounds on the rate of Hsp70 ATP hydrolysis.  
Steady state Hsp70 ATPase assays were carried out at 30 ºC in the presence of 100 µM test agent. 
The rates of ATP hydrolysis were converted from the free phosphate released at the 5 min 
timepoint and determined from two independent experiments (± S.D.). The relative “Fold 
change” of each compound compared to the rate of ATP hydrolysis in the presence of DMSO is 
indicated. 
Hsp70 ATPase × 104 (s-1) Fold change Compound 
DMSO 21 ± 6 -- 
CMC002042 22 ± 1 1.0 
PSI002042 18 ± 0 –1.2 
PSI002043 17 ± 5 –1.2 
PSI002049 14 ± 1 –1.5 
STW001222 16 ± 8 –1.3 
STW001150 15 ± 1 –1.4 
 
Table 11. Effects of the compounds on the rate of Hsp90 ATP hydrolysis.  
Steady state Hsp90 ATPase assays were carried out at 30 ºC in the presence of 100 µM test agent. 
The rate of ATP hydrolysis were converted from the free phosphate released at the 30 min 
timepoint and determined from at least two independent experiments (± S.D.).  The relative 
“Fold change” of each compound compared to the rate of ATP hydrolysis in the presence of 
DMSO is indicated. 
Hsp90 ATPase × 104 (s-1) Fold change Compound 
DMSO 7.1 ± 1.1 -- 
CMC002042 7.3 ± 0.9 1.0 
PSI002042 6.8 ± 2.0 1.0 
PSI002043 6.8 ± 0.9 1.0 
PSI002049 7.6 ± 1.4 1.1 
STW001222 7.3 ± 0 1.0 
STW001150 7.1 ± 0.1 1.0 
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4.7.2 Myosin ATPase assay results 
The natural product purealin inhibits myosin's Ca2+-stimulated ATPase activity with a 
concentration for half inhibition of 4 µM42. The new dynein inhibitors were therefore tested 
against the ATPase activity of rabbit skeletal muscle myosin II. Synthetic, racemic purealin75 
was tested as a positive control in the assay and an IC50 value of 36 ± 2 µM was obtained for it. 
In contrast, none of the new dynein inhibitors at up to 100 µM altered the myosin Ca2+-ATPase 
activity significantly (Table 12). 
 
Table 12. Effects of the compounds (100 µM) on the rate of myosin Ca2+-stimulated 
ATPase activity of rabbit muscle myosin II (25 µg/mL).  
The reaction was initiated with 2.5 mM ATP in the presence of myosin and the compounds. The 
rate of ATP hydrolysis was calculated from the free phosphate released (mean ± S.D., N = 4), 
and the relative “Fold change” caused by each compound as compared to the rate of ATP 
hydrolysis in the presence of DMSO is indicated. 
Compound Myosin Ca2+-ATPase (s-1) Fold change 
DMSO 0.17 ± 0 --- 
CMC002042 0.16 ± 0.01 -1.1 
PSI002042 0.20 ± 0.01 1.1 
PSI002043 0.19 ± 0.01 1.1 
PSI002049 0.17 ± 0.01 1.0 
STW001222 0.20 ± 0 1.2 
STW001150 0.18 ± 0 1.0 
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4.7.3 Microtubule polymerization assay results 
Compounds active in the GFP-GR nuclear translocation assay may act so by perturbing 
the cellular microtubule network. One example is the tubulin assembly inhibitor colcemid. It  has 
been shown to block corticosterone-stimulated GFP-GR nuclear translocation in 3T3 cells. 
Therefore, it was important to determine if the new dynein inhibitors had any effect on the 
microtubule network. The cellular levels of soluble and polymerized tubulin was determined 
cells were treated with the compounds. The 3617.4 cells were plated in 6-well plates and allowed 
to attach for 48 h, then treated with the indicated concentrations of different compounds. After 8 
h, cells were detached by trypsinization, washed with Hanks’ balanced salt solution (HBSS), 
then lysed in lysis buffer (see Chapter 2). The lysate was centrifuged at 14,000 rpm in an 
Eppendorf microcentrifuge. The supernatant (containing soluble tubulin fraction) and pellet 
(containing polymerized tubulin fraction) were dissolved in lysis buffer. Protein samples were 
analyzed by SDS-PAGE and Western blotting. Densitometric analyses were performed with 
ImageJ (v. 1.32j) software. Two controls were first included in this assay. A series dilutions of 
colchicine, a known tubulin assembly inhibitor, and paclitaxel, a known microtubule stabilizer, 
were used to treat cells for 8. Western blot analysis of polymerized (p) and soluble (s) tubulin 
fractions of 3617.4 cells showed that colchicine lowers the polymerized tubulin fraction in cells 
(Figure 60, upper). With the treatment of 320 nM colchicine, only 7% of the tubulin was in the 
polymerized form. However, treatment with paclitaxel increased the polymerized tubulin fraction 
(Figure 60, lower). The control results matched with the known roles of colchicine and paclitaxel 
in cells, providing the rationale for using this assay to check if the new dynein inhibitors perturb 
cellular microtubule networks. 
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Figure 60. Western blot analysis of polymerized (p) and soluble (s) tubulin fractions 
of 3617.4 cells with treatment of colchicine or paclitaxel. 
 
The dynein inhibitors were examined with this assay. The compounds at 100µM, as well 
as 1000nM paclitaxel and 320nM colchicine, were used (Figure 61). The results showed that the 
relative intensity of polymerized tubulin fraction in the presence of DMSO ranged from 0.9-1.6. 
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The dynein inhibitors caused the same. However, treatment with paclitaxel and colchicine gave 
relative intensities of 2.6 and 0.0, respectively. Therefore, the Western blot analyses of 
polymerized and soluble tubulin fractions of 3617.4 cells showed that the dynein inhibitors did 
not alter the microtubule content of cells. 
 
 
Figure 61. Western blot analysis of polymerized (p) and soluble (s) tubulin fractions 
of 3617.4 cells with treatment of dynein inhibitors. 
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The compounds’ abilities to disturb tubulin polymerization in vitro was also tested. 
Tubulin (from bovine brain) assembly reactions under various conditions were performed in the 
presence of 20 and 100µM PSI002049 (Figure 62). Polymer development was determined in 
temperature-controlled spectrophotometers by measuring turbidity at 350 nm. The experimental 
procedure is described in Chapter 2. Briefly, reaction mixtures consisting of tubulin (1 mg/ml), 
GTP (400 µM, if present) in 1M monosodium glutamate, pH 6.9, were prepared. Baselines were 
established after addition of all reaction components, except the test agents, to the cuvettes held 
at 0 oC. Test agents predissolved in DMSO were added and each reaction mixture (0.25 mL final 
volume) was subjected to the sequential temperature change studies at the indicated temperatures. 
The hypernucleating potencies of the test agents were also evaluated by turbidimetry, but in the 
absence of GTP.  
Tubulin with GTP. Test agent-induced turbidity profiles in the tubulin plus GTP system 
are shown in Figure 62A. In the presence of GTP and with no test agent, an increase in 
temperature to 30 oC resulted in a extensive assembly reaction as shown by the rapid rise in 
turbidity readings. When the temperature was rapidly dropped from 30 oC back to 0 oC, the 
polymer disassembled and the turbidity reading concordantly dropped quickly. A similar 
turbidimetry profile was observed with 20 and 100μM PSI002049. However, with 10µM 
colchicine, no polymer was observed from the beginning to the end of the experiment.  The 
result illustrated that PSI002049 did not inhibit the GTP-induced polymerization of tubulin. 
Tubulin with no GTP. Test agent-induced turbidity profiles in the tubulin without GTP 
system are shown in Figure 62B. In the presence of DMSO, when temperature was increased to 
30 oC and was rapidly dropped from 30 oC back to 0 oC, the turbidity reading remained 
unchanged. A similar turbidimetry profile was observed with 20 and 100μM PSI002049. 
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However, with paclitaxel (10µM and 20µM), an increase in temperature to 30 oC resulted in an 
extensive assembly reaction as shown by the rapid rise in turbidity readings. When the 
temperature was rapidly dropped from 30 oC back to 0 oC, the turbidity reading slowly and 
incompletely dropped.   The result illustrated that PSI002049 did not induce the polymerization 
of tubulin. 
 
 
Figure 62. Turbidity profiles of tubulin polymerization assay with stepwise 
temperature changes in the presence of PSI002049.  
A: In the presence of GTP. B: In the absence of GTP. 
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4.8 Antiproliferative activity of the UPCMLD hit compounds 
Finally, examination of the antiproliferative activities of the agents against the expansion 
of 3617.4 mouse mammary adenocarcinoma cells cultures (24 h or 72 h) showed that most of the 
six compounds had weak antiproliferative activity. Fifty percent growth inhibitory 
concentrations were in the mid-micromolar range (Table 13). In contrast, previous results 
showed synthetic purealin has no antiproliferative activity against human carcinoma cells75. 
 
Table 13. Antiproliferative activities of the test agents against 3617.4 cells. 
GI50 (µM) 
Compound 
24h 72h 
PSI002049 24 ± 2 27 ± 2 
PSI002043 40 ± 7 >50 
STW001222 >50 >50 
CMC002042 >50 42 ± 5 
PSI002042 20 ± 8 29 ± 2 
STW001150 40 ± 5 21 ± 5 
Paclitaxel >0.25 0.17 ± 0.05 
 
4.9 Discussion 
The strategy outlined here indicates that screening for compounds that block the transport 
of dynein’s cargo could be an efficient way to find new dynein inhibitors. Moreover, the 
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advantage of the initial cell-based strategy is that cell-permeating small molecules can be 
identified; i.e., those that give a phenotypic readout of dynein inhibition.  Importantly, the new 
dynein inhibitors exhibited specificity, as they did not interfere with GR binding, nor Hsp70 and 
Hsp90 ATPase activity. Since the one non-ATP-mimicking small molecule previously known to 
inhibit dynein, purealin, also has effects on myosin ATPase activity, it was considered prudent to 
screen the hits against this target as well. None of the new compounds here inhibited myosin. 
An important aspect of the small molecule inhibitors described here is that they do not 
compete for the nucleotide-binding site of the dynein motor domain. These cell-permeating 
dynein inhibitors are not ATP analogues and have very different chemical structures/scaffolds 
than previously identified dynein inhibitors; they are, therefore, a promising starting point for 
investigation of structure-activity relationships. The lead compound, PSI002043, has dynein 
ATPase inhibitory effect with an IC50 in the micromolar range. This compound could be a 
valuable tool to study detailed kinetics of the dynein motor and to dissect the mechanism of 
dynein-based cargo transport. Since dynein is related to many diseases, particularly 
neurodegenerative diseases and cancer28,104,105, a drug-like dynein inhibitor could also have 
therapeutic potential. 
Since the skeletal muscle myosin II inhibitor BTS12 and the Eg5 kinesin inhibitor 
monastrol10 have shown the potential for use as therapeutic agents, the present results identify an 
additional motor protein as a potential target for small molecule therapeutics. Further screening 
of libraries with diverse structures for inhibition of GFP-GR nuclear translocation, followed by 
validation with the biochemical assays described herein, will hopefully lead to a dynein inhibitor 
useful as a cell biology tool or perhaps even as a therapeutic agent. 
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The leading compound, PSI002049, showed effective inhibition against dynein motor 
domain ATPase (IC50=2.0µM). The compound was resynthesized by Dr. Stefan Werner in order 
to perform more cell based assays. However, the resynthesized PSI002049 showed pretty weak 
inhibitory effect against dynein motor domain ATPase with IC50 greater than 50µM. Therefore, 
old DMSO stock of PSI002049 was analyzed in LC-MS to check its purity. Unfortunately, the 
result showed that PSI002049 decomposed to different fractions upon current storage condidtion 
(-20oC) in DMSO (Figure 63). Different fractions (F1-F6) were collected and some of the 
fractions (F2, F3, F5 and F6) were also tested against dynein motor domain. The most active 
fraction F6 has IC50 = 36 ± 1 µg/mL. 
 
Figure 63. Dynein motor domain ATPase in the presence of different concentration 
of PSI002049 fractions. 
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5.0  BIOLOGICAL EALUATION OF HSP70 INHIBITORS 
5.1 Introduction 
The molecular chaperone Hsp70 plays very important roles in the cellular machinery for 
protein folding, for transport in concert with dynein (see previous chapters), and helps to protect 
cells from stress. It is known that overexpression of Hsp70 can lead to cellular transformation 
and tumorigenesis. Recent reports also show that inhibition of Hsp70 synthesis induces massive 
death of the breast cancer cells MDA-MB-468, MCF-7, SK-BR3 and BT-549, but has very little 
effect on WI-38 fibroblasts and HBL-100 nontumorigenic breast epithelial cells. Therefore, 
Hsp70 is a reasonable target for chemotherapeutic agents56.  
 It is known that the Ugi-Biginelli compound MAL3-101 inhibits Tag-stimulated Hsp70 
ATPase activity67. However, there no data regarding the antiproliferative activity of MAL3-101, 
or even its other cellular activities, has so far been determined. This chapter describes the 
screening of compounds related to MAL3-101 for activity against breast cancer cell 
proliferation.   
MAL3-101 is structurally considered as three parts: the Biginelli tetrahydropyrimidone 
part (shown as in red in Figure 64A); the Ugi part (shown as in blue in Figure 64A) and the 
linker between the above (shown as in purple in Figure 64A). The Biginelli part was synthesized 
by the Biginelli multicomponent reaction, a acid-catalyzed reaction between a β-ketoester 1, an 
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aldehyde 2 and urea 3 (Figure 64B). Then the Ugi part was obtained from an Ugi four 
component reaction (U-4CC), a condensation of the carboxylic acid 4 from Biginelli reaction, an 
isocyanide 5, an aldehyde 6 and an amine 7 to form α-aminoacyl amide derivatives (Figure 63C). 
 
Figure 64. General synthetic scheme of MAL3-101 analogues.  
A. Chemical structure of MAL3-101. Different color represents different part of the molecule. B. 
General scheme of Biginelli reaction. C. General scheme of Ugi reaction.  
 
5.2 Antiproliferative activity of the first library 
First, seven Biginelli/Ugi compounds, including MAL3-101, were obtained from the 
UPCMLD (Figure 65). Since biological inhibition of Hsp70 activity inhibits cell proliferation in 
different breast cancer cells, chemical inhibition of Hsp70 ATPase activity should also lead to 
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the same effect. SK-BR3 cells were used to test if the library had effects on cell proliferation. 
The MTS assay was used for determination of cell viability and cell counting. The procedure is 
described in Chapter 2. In short, cells were plated in 96-well plate and allowed to attach for 72 h. 
The cells were then treated with test agents for another 72 or 96 h and the MTS reagents were 
added. The results indicated that MAL3-101 has GI50s against SK-BR3 cells of 9.3 and 11 µM 
for 72 and 96 h, respectively, of drug treatment. However, the other six structurally related 
compounds did not show effective antiproliferative activity against SK-BR3 cells, especially 
when the cells were treated for 72 h (Table 14). Paclitaxel was used as a positive control in the 
MTS assay and it gave a GI50 in the low nanomolar range. This result supported the hypothesis 
that chemical inhibition of Hsp70 ATPase activity will inhibit breast cancer cell proliferation. 
The result also showed that MAL3-101 could be used as the starting point for breast cancer 
chemotherapeutic agent, although its structural related compounds failed antiproliferation assay.  
 
 
Figure 65. Chemical structure of MAL3-101 structural related compounds. 
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 Table 14. Antiproliferative activity of MAL3-101 and structural related compounds 
against SK-BR3 cells. 
GI50/µM SK-BR3 (1st trial) SK-BR3 (2nd trial) 
Exposure time/h 72 96 
MAL3-27 >50 41±2 
38±4 38±8 JB-99 
JB-78 >50 41±2 
MAL2-216 >50 ND* 
JB-116 >50 37±2 
40±0 JB-102 >50 
9.3±2.2 11±2 MAL3-101 
3.7±0.5 5.9±0.8 paclitaxel(nM) 
  
 The antiproliferative activity of MAL3-101 against another human breast cancer cell line, 
MDA-MB468, as well as against WI-38 fibroblast (a model for non-breast, “normal” cells) was 
also tested (Table 15). MAL3-101 gave a GI50 of 8.4µM against MDA-MB468 cell proliferation. 
However, MAL3-101 also showed antiproliferative activity against the WI-38 “normal” 
fibroblasts, with a GI50 of 15µM. Paclitaxel was again used as a positive control and it had a GI50 
of 1.7nM against MDA-MB468 cells but a value of  >100 nM against WI-38 cells.  
 
Table 15. Antiproliferative activity of MAL3-101 against MDA-MB468 and WI-38 
cell proliferation.  
GI50/µM MDA-MB468 WI-38 
Exposure time/d 6 5 
8.4±1.0 15±12 MAL3-101 
1.7±0.4 Paclitaxel(nM) >100 
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5.3 Antiproliferative activity of Ugi-Biginelli compounds 
More MAL3-101 analogues were synthesized by the UPCMLD in order to look for more 
active and more drug-like Hsp70 inhibitors. The compounds were first screened against SK-BR3 
cell proliferation with the MTS assay and GI50s were obtained. The results given below are 
classified according to chemical structural classes in order to help provide information about 
structure-activity relationships. 
 
 
Figure 66. Antiproliferative activity of Ugi-1 compounds.  
A. General chemical structure of Ugi-1 compounds. B. Antiproliferative activity of Ugi-1 
compounds against SK-BR3 cells for 72 h and the fold change of Tag-stimulated Hsp70 ATP 
hydrolysis in the presence of 300µM compounds (The Hsp70 data are courtesy of Prof. Brodsky 
group.) 
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The Ugi-1 compounds were MAL3-101 analogues with different aldehyde groups in the 
Biginelli part. The antiproliferative activities of the Ugi-1 compounds illustrated that most were 
active against SK-BR3 cells. Five out of 11 of the Ugi-1 compounds gave GI50s of less than 
10µM when the cells were treated for 72 h (Figure 66). 
 
 
Figure 67. Antiproliferative activity of Ugi-2 compounds.  
A. General chemical structure of Ugi-2 compounds. B. Antiproliferative activity of Ugi-2 
compounds against SK-BR3 cells for 72 h and the fold change of Tag-stimulated Hsp70 ATP 
hydrolysis in the presence of 300µM compounds (The Hsp70 data are courtesy of Prof. Brodsky 
group.) 
 
 
The Ugi-2 compounds were MAL3-101 analogues with different aldehyde groups in the 
Ugi part. The results showed that most of the Ugi-2 compounds were not effective against SK-
 112 
BR3 cell proliferation (Figure 67). Apparently, a changing in aldehyde group in the Ugi part of 
MAL3-101 causes a loss of antiproliferative activity. 
 
 
Figure 68. Antiproliferative activity of Ugi-3 compounds.  
A. General chemical structure of Ugi-3 compounds. B. Antiproliferative activity of Ugi-3 
compounds against SK-BR3 cells for 72 h and the fold change of Tag-stimulated Hsp70 ATP 
hydrolysis in the presence of 300µM compounds (The Hsp70 data are courtesy of Prof. Brodsky 
group.) 
 
 
Seven Ugi-3 compounds, which were MAL3-101 analogues with different amine groups 
in the Ugi part, were also examined. The antiproliferative activity of Ugi-3 compounds are 
shown in Figure 68. Most of Ugi-3 compounds were effective against SK-BR3 cell proliferation. 
The GI50 values for them were between 8.8 and 39µM (Figure 68). 
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 Figure 69. Antiproliferative activity of Biginelli acids.  
A. General chemical structure of Biginelli acids. B. Antiproliferative activity of Biginelli acids 
against SK-BR3 cells for 72 h and the fold change of Tag-stimulated Hsp70 ATP hydrolysis in 
the presence of 300µM compounds (The Hsp70 data are courtesy of Prof. Brodsky group.) 
 
 
 The antiproliferative activity of the Biginelli acids, which were MAL3-101 analogues 
without the Ugi part in an acid form, were also examined. None of the Biginelli acids showed 
effective antiproliferative activity against SK-BR3 cells, giving GI50s greater than 50 µM(Figure 
69). 
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 Figure 70. Antiproliferative activity of Biginelli esters.  
A. General chemical structure of Biginelli esters. B. Antiproliferative activity of Biginelli esters 
against SK-BR3 cells for 72 hrs. and the fold change of Tag-stimulated Hsp70 ATP hydrolysis in 
the presence of 300µM compounds (The Hsp70 data are courtesy of Prof. Brodsky group.) 
 
 
 As the Biginelli acids might not pass cell membranes, the Biginelli esters, MAL3-101 
analogues without the Ugi part in an ester form, were also examined. Again, GI50s were greater 
than 50 µM, the highest concentration used in the antiproliferation assay (Figure 70).  
5.4 Conclusions and discussion 
The Hsp70 and Hsp90 families of molecular chaperones play important roles in cellular 
processes, including protein folding, synthesis, transport and degradation. Hsp70 and Hsp90 
chaperones are also related to many human diseases, including cancer, cystic fibrosis, heart 
disease and some neurodegenerative syndromes (for review, see ref.58). Although there are 
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relatively more known Hsp90 inhibitors, and even some of them are currently used clinically, 
very few Hsp70 modulators have been identified (for review, see ref.106). The first efforts 
towards the discovery of more potent Hsp70 inhibitors as antibreast cancer agents is described 
here. Starting from the lead compound MAL3-101, which was prepared by the Wipf group and 
its biological discovered by the Day and Brodsky groups67, analogues of MAL3-101 were 
evaluated. The test of the first small library containing a small number of MAL3-101-related 
compounds did not provide agents with antiproliferative activity in SK-BR3 human breast cancer 
cells. A much larger library of MAL3-101 analogues was then obtained and screened against 
SK-BR3 cells. The antiproliferative activity of the MAL3-101 provided a practical structure-
activity relationship analysis based on the GI50s (Figure 71): the structure of the aldehyde group 
in Biginelli part is changeable, based on the results from Ugi-1 compounds; the structure of 
aldehyde group in Ugi part is required, based on the results from Ugi-2 compounds; the structure 
of the amine group in the Ugi part is changeable, based on the results of Ugi-3 compounds; the 
tetrahydropyrimidone part might be required to maintain the biological activity; the α-aminoacyl 
amide part is required; and the length of the linker might be important. 
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 Figure 71. Structure-activity relationship of MAL3-101 analogues.  
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6.0  CONCLUSIONS AND DISCUSSIONS 
 The work described here is the first practical evaluation for inhibitors of cytoplasmic 
dynein, and one of the first for inhibitors of its interacting protein Hsp70. Although dynein plays 
very important role in cells, especially in many types of cellular organelle transportation, very 
little is known about small molecule dynein inhibitors. This work started from purealin, a 
bromotyrosine-derived natural product isolated from the sea sponge Psammaplysilla purea, 
which inhibits the ATPase activity of isolated axonemal dynein and skeletal muscle myosin 
without competing for the ATP site on these motor proteins. A small library of synthetic purealin 
derivatives was examined for inhibition of cytoplasmic dynein heavy chain and cell growth. The 
compounds showed effective antiproliferative activity against L1210 mouse leukemia cells, but 
selective activities against a small panel of human carcinoma cell lines (MDA-MB231, PC-3. 
2008 and HT-29). Cytoplasmic dynein heavy chain was then purified from bovine brain and 
identified by MALDI-TOF-MS. Purealin and some of its analogues showed inhibitory effects 
against microtubule-stimulated ATPase activity of bovine cytoplasmic dynein heavy chain. A 
recombinant form of rat cytoplasmic dynein heavy chain motor domain was obtained and the 
purealin library was tested for inhibition of the ATPase activity of the motor domain. Purealin 
and a few of its analogues also showed inhibitory effects on microtubule-stimulated ATPase 
activity of the motor domain. The inhibitory effect of purealin was concentration-dependent and 
uncompetitive, supporting the hypothesis that it does not compete with the binding of ATP. 
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Since dynein is responsible for transport of the tumor suppressor protein p53 to the 
nucleus when DNA is damaged, a p53 nuclear translocation assay was established for evaluation 
of dynein inhibitors. A549 lung carcinoma cells were used for the p53 translocation assay. Cells 
were treated with a sub-lethal dose of a DNA damaging agent, camptothecin, to stimulate p53 
accumulation into the nucleus. Purealin showed weak inhibitory effects of p53 nuclear 
accumulation after DNA damage. An ArrayScan-based p53 nuclear translocation assay was set 
up in a HTS format. Dynein heavy chain knockdown experiments were also evaluated and 
optimized with dynein heavy chain siRNA, but this RNAi method proved not to be useful as a 
positive control in this assay due to the apparent long lifetime of dynein heavy chain in cells. 
 It is known that ligand-bound glucocorticoid receptor (GR) is translocated to the nucleus 
by dynein, via linkages provided by Hsp90, in concert with Hsp70 to immunophilins bound to 
the region of the dynactin-associated portion of the dynein complex. Chemical inhibition of 
dynein activity was envisioned as a useful means to block nuclear transportation of GR. A 
strategy for screening new dynein inhibitors was built based on a GFP-GR nuclear translocation 
assay using a mouse mammary adenocarcinoma cell line (3617.4) stably expressing GFP-rat GR.  
A library of compounds was obtained from the University of Pittsburgh Center for 
Chemical Methodology and Library Development (UPCMLD) that contained synthetic 
compounds wisely chosen as representatives from a larger set with considerable scaffold and 
physicochemical property variety. The 3617.4 cells stably expressing GFP-GR were used to 
screen for compounds that block hormone -stimulated GFP-GR nuclear translocation. Some of 
the compounds showed inhibitory effects in this asay. A GR competitor assay and a GR binding 
assay showed that the compounds active in the GFP-GR nuclear translocation assay did not 
compete for GR binding nor affected the GR complex.  
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Dynein motor domain ATPase assays were then performed to determine the compounds’ 
direct effects on the target, and five were found to be new dynein ATPase inhibitors. The leading 
compound gave an IC50 value against dynein ATPase in the micromolar range. Kinetic study of 
these compounds showed that they did not compete for the ATP binding site on cytoplasmic 
dynein’s motor domain. The new dynein inhibitors also showed no significant effect on Hsp70 
and Hsp90 ATPase activities. Furthermore, results from an assay for myosin ATPase indicated 
that the new dynein inhibitors had no observable effect on Ca2+-ATPase activity of skeletal 
muscle myosin II. The results therefore suggest that this strategy provides a practical way to find 
new cell-permeable dynein inhibitors via screening the compounds that could block the 
transportation of dynein’s cargo.  
Molecular chaperones are required for protein maturation and play critical roles in the 
pathogenesis of many human diseases.  Previous data indicate that the Hsp70 chaperone class is 
induced in breast cancer cells and that antisense-mediated knock-down of Hsp70 triggers breast 
cancer cell apoptosis in vitro.  These results indicate that Hsp70s represent a new target for 
breast cancer therapy and that small molecule inhibitors of Hsp70s might similarly trigger breast 
cancer cell death.  To test this hypothesis, breast cancer cell growth was examined in the 
presence or absence of a small molecule inhibitor of Hsp70 co-chaperone interaction, MAL3-
101, as well as several compounds structurally related to MAL3-101. Varying concentrations of 
each compound were added to SK-BR3 breast cancer cells in two independent experiments and 
their GI50s were determined. The GI50 for MAL3-101 was 10 ± 2µM; as a positive control, 
paclitaxel was shown to inhibit growth with a GI50 of 3.7 ± 0.5nM. A first small library of 
MAL3-101-related compounds were less effective than MAL3-101, most likely because their 
impact on Hsp70 ATPase activity and modulation by Hsp70 co-chaperones was less pronounced.   
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A larger library of MAL3-101 compounds was prepared by the UPCMLD and evaluated for 
inhibition of SK-BR3 cell proliferation. Some of the analogues showed effective antiproliferative 
activities, providing a valuable first qualitiative structure-activity relationship. These data 
support the importance of future efforts to identify new and more potent chaperone modulators 
that may prove valuable to combat breast cancer. 
The research provided here showed the rationality of screening for dynein-specific 
inhibitors via phenotypic screening assays. However, there is still a need to find more potent 
dynein inhibitors. Theoretically, any phenotypic assay showing the inhibition of transportation of 
dynein’s cargo (e.g., p53, GR, adenovirus, HIV-Vpr, VSVG-GFP107, etc.) could be used to set up 
a high throughput screen for dynein ATPase inihibtiors. Since the p53 and GR nuclear 
translocation assays were implemented here into at worst what could be considerd a medium 
throughput format, those two assays should be transferred to high throughput first. The assays 
can be performed in 384-well format, cells plated with a liquid handling plate processor (e.g., the 
Titertek MAP-C plate processor) and cell density optimized. Compound/reagent addition could 
be performed with Biomek2000 or SymBiot I (single channel) or XVI (16 channel) liquid 
handlers. DMSO tolerance, the time course for appropriate responses from the positive and 
negative controls, the concentration-dependence of the nuclear translocation stimulator 
(camptothecin/etoposide in the p53 nuclear translocation assay, dexamethasone in GFP-GR 
nuclear translocation assay) should be determined next for optimization. The assay with different 
conditions and different controls, e.g., known dynein inhibitors, should be repeated several times. 
Maximum signal (with the positive control) and minimum signal (with the negative control), 
signal-to-background, signal-to-noise, coefficients of variance (CV), and Z’-factors should also 
be obtained. The CV and Z’-factor can be used to evaluate the suitability and compatibility of the 
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assay for HTS. The hits from the cellular phenotype HTS assay should be tested for validation 
following the strategy described: inhibition of dynein heavy chain ATPase activity; inhibition of 
Hsp90, Hsp70 and myosin ATPase; perturbation of tubulin assembly; and GR binding by  
fluorescence polarization.  
Adenovirus is a 70-100 nm diameter non-enveloped dsDNA virus that replicates in the 
cell nucleus. It is known that dynein is responsible for the transportation of the naked virus 
particle after adenovirus escapes from the endosome13. It is also known that the addition of the 
microtubule-disrupting agent nocodazole, microinjection of an antibody to the dynein 
intermediate chain, and overexpression of the dynamitin subunit of dynactin will prevent 
perinuclear accumulation of adenovirus32-34. Therefore, a cytoplasmic dynein inhibitor shold give 
a similar effect. The adenovirus nuclear translocation assay should be performed in the A549 
human lung carcinoma cell line, as these cells have a large cytoplasm that enables clear 
determination of viral accumulation at the nucleus or otherwise. A form of Cy3 could be 
covalently coupled to adenovirus as described33 and the resulting fluorescent virus can be 
produced in amounts suitable for use in high-throughput assays. The A549 cells would be 
infected with the Cy3-adenovirus at a multiplicity of infection (m.o.i.) of 100 and incubated at 
4°C for 40 min. The cells would then be washed to remove unbound virus and incubated at 37°C 
for 60 min. The 4°C incubation followed by washing enables the infectious process to be 
synchronized because microtubules partially disassemble at this temperature. Such 
synchronization would result in a very clear end point for the assay. Nucleus-localized 
fluorescent virus should be easily visible in both live and fixed cells. The cells should as be fixed 
and stained for microtubules as described above to insure that the test agent does not perturb 
cellular tubulin assembly/disassembly.  
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